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Summary 
Stimulatory or superagonistic (SA) CD28-specific monoclonal antibodies (mAbs) are potent 
polyclonal activators of regulatory T cells and have proven highly effective as treatment in a 
wide range of rodent models for autoimmune and inflammatory diseases. In these models, a 
preferential activation of regulatory T cells was observed by in vivo administration of 
CD28SA. In stark contrast, human volunteers receiving TGN1412, a humanized CD28-
specific mAb, experienced a life-threatening cytokine release syndrome during the first-in-
man trial. Preclinical tests employing human peripheral blood mononuclear cells (PBMC) 
failed to announce the rapid cytokine release measured in the human volunteers in response 
to TGN1412.  
 The aim of this thesis project was to find an explanation of why standard PBMC 
assays failed to predict the unexpected TGN1412-induced "cytokine storm" observed in 
human volunteers. CD28 superagonists can activate T cells without T cell receptor (TCR) 
ligation. They do depend, however, on “tonic” TCR signals received by MHC scanning, 
signals that they amplify. PBMC do not receive these signals in the circulation. Short-term in 
vitro preculture of human PBMC at a high cell density (HDC) resulted in massive cytokine 
release during subsequent TGN1412 stimulation. Restoration of reactivity was cell-contact 
dependent, associated with TCR polarization and tyrosine-phosphorylation, and blocked by 
HLA-specific mAb. In HDC, both CD4 T cells and monocytes functionally mature in a 
mutually dependent fashion. However, only CD4 memory T-cells proliferate upon TGN1412 
stimulation, and were identified as the main source of pro-inflammatory cytokines. 
Importantly, responses to other T-cell activating agents were also enhanced if PBMC were 
first allowed to interact under tissue-like conditions.  
 A new in vitro protocol is provided that returns circulating T-cells to a tissue-like status 
where they respond to TGN1412 stimulation, and it might represent a more reliable 
preclinical in vitro test for both activating and inhibitory immunomodulatory drugs. 
 Finally, the surprising observation was made that the IgG1 “sibling” of TGN1412, 
which is of the poorly Fc receptor-binding IgG4 isotype, has a much lower stimulatory activity. 
We could exclude steric hindrance as an explanation and provide evidence for removal of 
TGN1112 from the T-cell surface by trans-endocytosis. 
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Zusammenfassung 
Stimulatorische oder superagonistische (SA) CD28-spezifische monoklonale Antikörper 
(mAbs) (CD28SA) haben sich in diversen Nagetiermodellen für Autoimmunerkrankungen 
sowie für inflammatorische Erkrankungen als effektive Behandlungsmöglichkeit erwiesen. In 
diesen Modellen konnte nachgewiesen werden, dass CD28SA-Injektionen zu einer 
verstärkten Aktivierung regulatorischer T-Zellen in führen. Entgegen diesen Beobachtungen 
im Tiermodell reagierten die Teilnehmer einer ersten klinischen Studie auf die  Administration 
des humanisierten CD28SA TGN1412 mit einer akut lebensbedrohlichen systemischen 
Zytokinausschüttung. Vorklinische Studien an humanen mononukleären Zellen des Blutes 
(PBMC) hatten keinen Hinweis auf eine mögliche plötzliche Zytokinausschüttungen als 
Reaktion auf TGN1412 gegeben.  
 In der vorliegenden Arbeit wurde versucht eine Erklärung zu finden, warum PBMC-
basierte  Tests, wie sie  vorklinischen Studien als Standard eingesetzt werden, nicht auf den 
unerwarteten TGN1412-induzierten „Zytokinsturm“ der Probanden hinwiesen. CD28SA 
aktivieren T-Zellen ohne Ligation des T-Zell Rezeptors (TCR). Jedoch werden zur CD28SA-
abhängigen Aktivierung von T-Zellen „tonische“ TCR Signale benötigt, die durch MHC 
Scanning der T-Zellen an der Oberfläche anderer Zellen erzeugt werden. PBMC, welche sich 
in der Zirkulation befinden, erhalten diese „tonischen“ TCR Signale nicht. Kurzzeitige 
Vorkultur humaner PBMC bei hoher Zelldichte (high-density culture, HDC) führte zu einer 
starken Zytokinantwort bei nachfolgender TGN1412 Stimulation. Diese wiedererlangte 
Reaktivität gegenüber TGN1412 ging mit Tyrosin-Phospholrylierung sowie der Polarisierung 
von TCR  Molekülen einher, war abhängig von Zellkontakten und konnte durch HLA-
spezifische mAbs geblockt werden. Während der HDC durchlaufen sowohl CD4 T-
Gedächtniszellen, als auch Monozyten eine voneinander abhängige funktionelle Reifung. 
TGN1412-induzierte Zellproliferation beschränkt sich jedoch auf CD4 T-Gedächtniszellen, 
die auch die Hauptquelle der  proinflammatorische Zytokine sind.  Antworten auf weitere T-
Zell aktivierende Agenzien waren ebenfalls erhöht, wenn PBMC zunächst auf gewebeartige 
Bedingungen zurückgesetzt wurden.  
 Die vorliegende Arbeit beschreibt damit ein neuartiges in vitro Protokoll für humane 
PBMC, welches T-Zellen der Zirkulation in einen gewebeartigen funktionellen Status 
versetzt, in welchem sie auf TGN1412 antworten. Dieses Protokoll könnte auch einen 
verlässlicheren vorklinischen in vitro Test sowohl für aktivierende als auch für inhibierende 
immunmodulatorische Medikamente darstellen. 
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Im letzten Teil der Arbeit wird die erstaunliche Beobachtung vorgestellt, dass TGN1112, ein 
IgG1 Antikörper mit gleicher Spezifität wie der IgG4 Antikörper Antikörper TGN1412, trotz 
seiner höheren Affinität für Fc-Rezeptoren eine viel geringere stimulatorische Aktivität zeigt. 
Sterische Hinderung konnte als eine mögliche Erklärung ausgeschlossen werden. Vielmehr 
scheint das Entfernen von TGN1112/CD28 Komplexen von der T-Zelloberfläche durch 
Trans-Endozytose eine mögliche Erklärung für die geringere Aktivität zu sein.  
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1. Introduction 
1.1. Immune system 
The immune system represents the body's defense against pathogens. It consists of two 
main branches, the innate and the adaptive immune system. Innate immunity is the first line 
of defense against microbes. It is comprised by (a) physical and chemical barriers such as 
epithelia and the chemicals produced by epithelial surfaces; (b) phagocytic cells (neutrophils, 
macrophages), dendritic cells (DC), and natural killer cells (NK cells); (c) proteins in the 
blood, for example complement system components; and (d) cytokines, proteins that 
orquestrate numerous functions during an immune response. The mechanisms of innate 
immunity recognize structures that are common on groups of related pathogenic organisms, 
for example, innate immune cells express pattern recognition receptors (PRR) that recognize 
pathogen-associated molecular patterns (PAMPs) expressed on microbes (Reviewed in 
Luster 2002). 
 Adaptive immunity, on the other hand, is activated upon antigen encounter and it is 
tailored to the specific threat. An important characteristic of adaptive immunity is that it 
generates memory, so if repeated exposures to the microbe occur the protective immune 
response will be faster, highly specific and more effective. The main effectors in an adaptive 
immune response are lymphocytes and their secreted antibodies (Ab), and they recognize 
antigens either on the cell surface of microbes or presented by DC in the form of peptides. 
There are two main types of adaptive responses. One is humoral immunity comprised by B 
cells and their secreted antibodies, which can block infections or coat extracellular microbes 
to be recognized by phagocytes or by complement in order to clear them. The other is cell-
mediated immunity, which protects the body from intracellular pathogens such as viruses and 
some bacteria. It is mediated by T cells, which can activate macrophages to destroy 
phagocytosed microbes or can recognize and kill infected cells (Reviewed in Luster 2002). 
 A very important feature of adaptive immunity is tolerance, meaning that it has the 
ability to discriminate between self and non-self, so the body does not react to self-antigens. 
This is done via several mechanisms such as elimination of self-reactive lymphocytes during 
their development, or inactivation or suppression of these cells by regulatory T cells (Tregs) 
(Sakaguchi 2004). Tregs are major players in maintaining peripheral tolerance and in 
regulating the degree and duration of immune responses. They can suppress CD4 and CD8 
T cell responses through cell-cell contact and IL-10 secretion, and they have shown to be 
very important in suppressing organ-specific and systemic autoimmunity in rodent models 
(Reviewed in Leipe et al. 2005). Disruption or dysregulation on any key mechanism involved 
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in tolerance development or maintenance can cause the body to "attack" itself, leading to the 
onset of autoimmune diseases (Reviewed in Davidson and Diamond 2001). 
1.1.1. T cells 
T cells are part of the adaptive immune system and are the mediators of cellular immunity. 
Their precursors are generated in the bone marrow but they mature in the thymus. The two 
major subsets are CD4+ T cells and CD8+ cytotoxic T lymphocytes (CTL). CD4+ regulatory T 
cells are another subset (Hori, Nomura, and Sakaguchi 2003), and all three of these subsets 
express an antigen receptor called !" receptor (Reviewed in Kuhns and Davis 2012). 
Another T cell population are the #$ T cells with a functionally distinct type of antigen 
receptor (Reviewed in Pang et al. 2012). 
1.1.1.1. Structure of the T cell receptor and T cell receptor complex 
The !" T cell receptor (TCR) is a heterodimer composed of two transmembrane polypeptide 
chains, the ! and the " chain, each consisting of one Ig-like N-terminal variable domain, one 
Ig-like constant domain, a hydrophobic transmembrane region, and a short cytoplasmic 
region (Clevers et al. 1988). 
 The human !" TCR complex consists of one !" TCR heterodimer noncovalently 
linked to one #% CD3 heterodimer, one $% CD3 heterodimer, and one disulfide-linked && 
homodimer. These TCR-associated proteins play a role in intracellular signal transduction 
and not in antigen recognition, by phosphorylation of their intracellular immunoreceptor 
tyrosine-based activating motifs (ITAM) (Reviewed in Smith-Garvin, Koretzky, and Jordan 
2009). 
1.1.1.2. T cell activation and costimulation 
T cells have a high specificity for the antigen that elicits the response. After activation cells 
proliferate and generate a large number of functional effector cells from a small pool of naive 
lymphocytes, some of which become memory cells and remain for long periods of time in the 
body maintaining protective immunity against reinfection (Sprent and Surh 2002). 
 T cells are activated through the T cell receptor (TCR) complex after peptide loaded 
MHC molecules on antigen presenting cells (APC) are recognized, which is termed “signal 
1”. The second signal or “signal 2” is given by costimulatory molecules expressed on 
activated APC. Lack of costimulation leads T cells to an anergic state in which they are 
refractory to restimulation. When both signals are present clustering of coreceptors around 
the TCR complex is initiated, and ITAM tyrosine residues are phosphorylated by active Src 
family kinases, events that initiate signal transduction. A supra-molecular activation cluster 
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(SMAC) forms, a structure resembling a bulls-eye with two concentric rings. It consists of a 
central SMAC (cSMAC) and a peripheral SMAC (pSMAC). The cSMAC is formed by the TCR 
complex, CD4 or CD8 coreceptors, costimulation receptors (such as CD28), enzymes such 
as PKC-' and adaptor proteins. The pSMAC is formed by integrins such as talin and 
lymphocyte-associated antigen 1 (LFA-1), which main role is to stabilize the T-cell-DC 
interaction. CD45, known also as common leukocyte antigen, stays outside the pSMAC in an 
area termed distal SMAC (dSMAC) (Monks et al. 1998). 
1.1.1.2.a. T cell receptor signaling 
The first steps following TCR-MHC+peptide recognition involve many phosphorylation events 
of ITAMs, as well as the activation of downstream tyrosine kinases. The CD4 and CD8 
coreceptors participate in the signal transduction by bringing the Src family kinase Lck 
(lymphocyte-specific protein tyrosine kinase) close to the CD3 and & ITAMs, which 
phosphorylates them together with the kinase Fyn. Subsequently, ZAP-70 is recruited and a 
cascade of phosphorylation events is initiated which ends up with activation of transcription 
factors (NFAT, NF(B and AP-1), gene transcription and protein expression (Reviewed in 
Smith-Garvin, Koretzky, and Jordan 2009). 
1.1.1.2.b. CD28 costimulation 
The most important and best characterized costimulatory receptor expressed on T cells is 
the homodimeric glycoprotein CD28 (Hara, Fu, and Hansen 1985), which in humans is 
expressed in approximately 95% of CD4+ T cells and 50% of CD8+ T cells (Lum et al. 1982). 
The ligands of CD28 are CD80 (B7-1) and CD86 (B7-2) expressed on activated APC 
(Sharpe and Freeman 2002). CD80 is a homodimer whereas CD86 is a monomer; 
nevertheless the CD28 homodimer binds to both molecules monovalently due to steric 
interference (Collins et al. 2002; Evans et al. 2005). 
CD28 is part of the immunoglobulin family of costimulatory receptors (Hansen, Martin, 
and Nowinski 1980; Gmunder and Lesslauer 1984), together with cytotoxic T-lymphocyte 
antigen 4 (CTLA-4 or CD152) (Dariavach et al. 1988), programed-death receptor 1 (PD-1), 
inducible T-cell costimulator (ICOS or CD278) (Hutloff et al. 1999; Tezuka et al. 2000) and B- 
and T-lymphocyte attenuator (BTLA) (Watanabe et al. 2003). CTLA-4, PD-1 and BTLA are 
inhibitory receptors, while CD28 and ICOS are predominantly enhancing T-cell activation 
(Sharpe 2009). 
The more robust T cell-signal enhancer is CD28. It promotes T cell proliferation, 
cytokine production, cell survival, and cellular metabolism. It can be addressed in vitro with 
monoclonal antibodies (mAbs), in combination with anti-TCR mAbs, leading to full T-cell 
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activation. Recently, Sanchez-Lockhart et al. (2011) showed that TCR ligation might lead to a 
conformational change of the extracellular domains of CD28, enabling ligand binding and 
signaling, a mechanism similar to integrin inside-out signaling. CD28 ligation leads to an 
intracellular signaling cascade that is initiated by phosphorylation of a tyrosine residue and 
subsequent recruitment of the p85 subunit of phosphatidyl-inositol 3-kinase (PI3K), although 
its role is still controversial. Grb2 and GADS are adaptor proteins that can bind the same 
region as PI3K and are also involved in signaling. Another molecule that is also likely 
involved in CD28 signaling, but binds to a different region, is Lck. Binding of PI3K and the 
adaptor proteins initiates signaling pathways that lead to activation of the transcription factors 
AP-1, NF(B and NFAT, leading to T-cell survival signals, IL-2 production, and cell 
proliferation (Reviewed in Boomer and Green 2010). 
While CD28 costimulation represents a stimulatory signal for T cells, there is a 
parallel mechanism which competes for CD80/86 binding and gives a negative signal for T-
cell response termination, and that is the CTLA-4 homodimer, which is upregulated on 
effector T cells upon activation and constitutively expressed on regulatory T cells. CTLA-4 
binding affinity is 20-fold higher to CD80 and up to 100-fold higher to CD86 than CD28. 
Moreover, CTLA-4 binds to ligand in a bivalent fashion increasing the avidity considerably, 
although for CD28 it is still not clear if it binds mono- or bivalently in the immunological 
synapse (Sanchez-Lockhart, Kim, and Miller 2011). CTLA-4 plays an important role in 
keeping immune responses in check (Collins et al. 2002). 
 
1.2. Immune pathologies 
Immune responses are tightly controlled. Nevertheless the possibility that a person's immune 
system reacts against self-antigens causing damage exists. There are two different 
circumstances in which the body can harm itself, one is under excessive inflammatory 
conditions tissue can be damaged by the immune system, which is sometimes grouped 
under "immune-mediated inflammatory diseases" or "hypersensitivity diseases", but they are 
not associated with recognition of self-antigens. On the other hand, if tolerance is breached 
immune cells can react against self-antigens causing damage, which is termed 
"autoimmunity". It results from a dysregulation of tolerance mechanisms on T and B cells. 
The major factors contributing to the development of autoimmune diseases are genetic 
susceptibility and environmental triggers, such as infections and tissue injury. 
 Rheumatoid arthritis (RA), a very common autoimmune disease, is associated with 
high levels of TNF production, which seems to down-modulate the suppressive function of 
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human CD4+CD25hi Treg cells through TNF receptor II (TNFRII) by lowering FOXP3 mRNA 
as well as protein expression (Valencia et al. 2006). An approach to treat RA, besides the 
already established TNF blockade, could include manipulation of the Treg compartment. 
Adoptive transfer of Treg cells has proven beneficial in animal models of RA, but the 
consequences of these kind of therapy in humans remains to be established (Fox 2012). 
1.2.1. Classic therapies to control autoimmune diseases 
There are over 80 types of autoimmune diseases affecting the human population. The need 
for treatments that ameliorate the symptoms or even cure the disease are clearly necessary 
(Dugdale and Zieve 2011). There are numerous treatments that are prescribed to control or 
reduce the immune response. Some of these immunosuppressive drugs include 
corticosteroids (such as prednisone, methylprednisolone), and non-steroid drugs such as 
azathioprine, cyclophosphamide, mycophenolate, which inhibit T and B cell proliferation by 
different mechanisms; rapamycin, which prevents activation of T cells and B-cells by 
inhibiting their response to interleukin-2 (IL-2); tacrolimus or cyclosporine, both of which 
inhibit calcineurin and therefore activation of NFAT, T-cell signal transduction and IL-2 
transcription, and methotrexate, an antimetabolite and antifolate drug which inhibits purine 
metabolism,  consequently blocking the synthesis of DNA, RNA, and proteins. These 
immunosuppressive drugs are used to prevent transplant rejection, cancer treatment or to 
ameliorate the symptoms in autoimmune diseases (Wikipedia). 
1.2.2. Biologics 
Biologics are genetically engineered proteins derived from human genes. They are designed 
to inhibit key components of the immune system that promote inflammation, therefore they 
are much more specific than the classical treatments. 
 Many biologics are used to treat a wide range of autoimmune diseases such as 
systemic lupus erythematosus, multiple sclerosis, type 1 diabetes, ulcerative colitis, as well 
as a cancer treatment, because they target elements involved in inflammation processes. 
The gold standard treatment for many autoimmune diseases associated with excessive TNF 
release are TNF blockers in combination with methotrexate, which in many patients changes 
the course of the disease from progressive damage to a manageable chronic inflammation 
(Bingham 2012). Although TNF inhibitors are quite effective in ameliorating the symptoms 
they are not specific to the disease and are associated with a variety of side effect such as 
lymphoma, infections, congestive heart failure, lupus-like syndrome, induction of auto-
antibodies and injection site reactions, although the risk of these side effects is very low 
(Scheinfeld 2004). 
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1.3. Immunomodulatory monoclonal antibodies 
Antibodies directed against inflammatory mediators or cell surface molecules are an 
attractive approach to develop immune therapies for a wide range of diseases. In 1986, the 
first monoclonal antibody (mAb) for human therapy was approved by the FDA, Muronomab 
(Orthoclone OKT3), and since then more than 30 mAb have been approved and are currently 
used to treat autoimmune diseases, cancer and other maladies. 
1.3.1. Muronomab (Orthoclone OKT3) 
OKT3 was used as an immunosuppressant against transplant rejection. However, because 
of its numerous side effects, better-tolerated alternatives and declining usage, OKT3 was 
removed from the market in 2010 (Reichert 2012).  
It is a mouse mAb that binds the epsilon chain of the CD3 molecule on the T-cell surface 
initially leading to T-cell activation and systemic cytokine release, namely a cytokine release 
syndrome (CRS) that can be controlled with the use of corticosteroids (Gaston et al. 1991), 
but subsequently results in CD3+ cell depletion (Stankova, Hoskin, and Roder 1989). T cell 
activation is mediated by Fc receptor (FcR) cross-linking on the surface of cells such as 
monocytes (Rinnooy Kan et al. 1986; Landegren, Andersson, and Wigzell 1984). The 
therapeutic effect consists in T-cell depletion by opsonization and T-cell function blockade by 
removal of CD3 from the cell surface (Goldstein 1987). 
 
1.4. Regulatory T cells as a target for therapy 
“Natural” regulatory T cells are key effectors in keeping immune responses in check. They 
protect against development of autoimmunity and other immunopathologies such as allergies 
(Sakaguchi et al. 2006). Because of these features, manipulation of the Treg-cell 
compartment represents an attractive target for therapy. Tregs are characterized by CD4 and 
CD25 (IL-2R!) expression, as well as the transcription factor FoxP3 (Fontenot and Rudensky 
2005). The high levels of CD25 expression are related to the dependance of Tregs on IL-2 
for their survival and activation, as seen in knock-out animal models where the lack of IL-2 or 
IL-2R gives a phenotype of an autoimmune lymphoproliferative disease (Papiernik et al. 
1998; Maloy and Powrie 2005; Furtado et al. 2002; Krämer, Schimpl, and Hunig 1995; 
Schimpl et al. 2002; Wolf, Schimpl, and Hunig 2001). Besides FoxP3 expression, another 
difference with CD4+ effector cells is that Tregs constitutively express CTLA-4 (Takahashi et 
al. 2000). This might be involved in their suppressive function, although it is still not clear 
 19 
 
whether CTLA-4 might play a role in cis regulation of Treg function or if the role is in negative 
regulation of the CD4+ T-cell compartment (Reviewed in Sansom and Walker 2006). 
Recently, Qureshi et al. (2011) demonstrated a cell-extrinsic inhibitory effect of CTLA-4+ cells 
over T-cell activation via CD28. They suggested a model in which activation of conventional 
T-cells or Treg cells promotes the removal and degradation of CD80 and CD86 from the 
surface of APC by CTLA-4, a process termed “trans-endocytosis”. 
 CD28 is expressed on both regulatory and conventional T cells. CD28 expression on 
Tregs seems to play an important and non-redundant role in the generation, homeostasis, 
and activation of the cells. This is supported mainly by the finding that CD28-deficient mice 
have a reduced Treg cell compartment (Salomon et al. 2000). As mentioned, IL-2 production 
by conventional T cells depends on CD28 costimulation. When this cytokine is produced, 
Treg cells are activated and expanded, which in turn switch off IL-2 production by effector 
cells. Manipulation of CD28 costimulation is a subject of interest in the field of immunological 
therapies, since this molecule is involved in homeostasis of both CD4+ effector and 
regulatory T cells. 
 A therapy engineered with the aim of blocking T-cell activation was the generation of 
CTLA-4-Ig, which is a recombinant fusion protein consisting of the extracellular domain of 
CTLA-4 fused to the Fc portion of IgG. It competes with binding to CD80 and CD86, blocking 
CD28 costimulation (Reviewed in Najafian and Sayegh 2000). CTLA-4-Ig has been used as 
a succesful therapy on rheumatoid arthritis (Nogid and Pham 2006). 
 Functional impairment or reduced numbers of Treg cells have been associated with 
generation of autoimmunity in several animal models (Reviewed in Sakaguchi 2000). In 
humans, defects in the Treg compartment have also been associated with autoimmune 
diseases such as multiple sclerosis (Viglietta et al. 2004), rheumatoid arthritis (Ehrenstein et 
al. 2004), or type-1 diabetes (Lindley et al. 2005). Therefore, manipulation of the Treg 
compartment is of great interest in the development of immune therapies. 
1.4.1. Conventional and superagonistic anti-CD28 mAbs 
The CD28 molecule was first identified in humans by the use of mAbs. These showed to act 
as T cell costimulators during polyclonal T cell activation in vitro (Hara, Fu, and Hansen 
1985). The first mAbs directed against CD28 in mice (Gross, Stjohn, and Allison 1990) and 
rat (Tacke et al. 1995) were developed much later. These also showed to act as 
costimulators in vitro, in combination with TCR activation, but were not stimulatory by 
themselves. This kind of CD28-specific mAb is referred to as “conventional”. 
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 When mAbs recognizing rat CD28 were generated, two functionally distinct 
categories were detected, conventional antibodies which acted as “signal 2” during T cell 
activation, and another kind that surprisingly activated T cells without the need of TCR 
ligation, termed “superagonistic” (Tacke et al. 1997). This unexpected functional difference 
was not related to the antibody isotype or differential binding avidity. Instead it showed to be 
related to the biding epitope on the CD28 molecule (Luhder et al. 2003). Conventional mAbs 
bind close to the ligand binding site of CD80/86, while superagonistic mAbs bind laterally to 
the CD28 molecule, specifically to the C))D loop (Figure 1A and B). Human, mouse and rat 
conventional and superagonistic monoclonal antibodies bind to CD28 as shown in Figure 1 
(Luhder et al. 2003; Dennehy et al. 2006; Evans et al. 2005). 
 The mode of binding of human superagonistic or mitogenic !CD28 mAbs was 
determined by cocrystralization of Fab fragments of the antibody with recombinant soluble 
CD28, and a lateral binding mode was observed (Evans et al. 2005). This suggests that 
CD28SA might crosslink CD28 molecules on the cell surface forming a lattice (Figure 1C). 
CTLA-4 mode of binding to its natural ligands is also bivalent, while CD28 binds 
monovalently (Collins et al. 2002). It has been hypothesized that the bivalent mode of binding 
of CD28SA, resembling the one of CTLA-4, may be related to their activation properties on T 
cells; or, on the other hand, its possible that the monovalent binding of CD28 is a mechanism 
by which the activation signal stays under the control of the TCR (Dennehy et al. 2006).  
1.4.1.1. Signaling pathways of CD28 superagonistic mAbs 
CD28 superagonists stimulate T cells without TCR engagement by inducing intracellular 
signaling cascades (Bischof et al. 2000; Hünig and Dennehy 2005). Importantly, during 
CD28SA T cell activation, the proximal components of the TCR signaling machinery TCR & 
chain and ZAP-70 do not show phosphorylation above background levels (Dennehy et al. 
2007; Dennehy et al. 2003; Luhder et al. 2003). However, it has been observed that CD28SA 
T cell stimulation depends on constitutive proximal TCR signals, or what is called “tonic 
signals”. These signals are amplified at the level of the SLP-76 signalosome, where the 
adaptor molecule Vav1 plays an essential role (Dennehy et al. 2007). 
 CD28 superagonist stimulation polarizes resting T cells predominantly into a Th2 
phenotype (Rodriguez-Palmero et al. 1999). It also induces a significant upregulation of Bcl-
xL, which is involved in the FAS-L pathway, and there is no induction of CD95L expression, 
which translates into T cells being more resistant to apoptosis (Kerstan and Hunig 2004). 
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Figure 1. Binding of the superagonistic and conventional !CD28 monoclonal 
antibodies to CD28. A. Three dimensional model of the extracellular portion of 
human CD28 (blue) showing the binding epitopes of conventional rat and mouse 
CD28-specific mAb (yellow), of rat and human superagonistic !CD28 mAb (red), and 
of B7 molecules (CD80/86) (green, MYPPPY loop) (Luhder et al. 2003)§. B. Simplified 
view of the binding epitopes on CD28 molecules; colors represent same as in A. C, D. 
Mode of binding of CD28SA (dark grey) and conventional (light grey) !CD28 mAbs to 
the extracellular portion of the CD28 homodimer (blue) (B-D from Beyersdorf, Hanke, 
et al. 2005)*. 
 
1.4.2. In vitro regulatory T cell expansion by !CD28 conventional and 
superagonistic mAbs 
CD28 costimulation is necessary for the in vivo generation of Treg cells, as seen in a model 
of CD28 and/or B7 molecules deficient mice (Salomon et al. 2000). The cytokine IL-2 is also 
crucially involved in the generation and homeostasis of Treg cells (Malek and Bayer 2004; 
Setoguchi et al. 2005). Therefore, efficient in vitro expansion of Treg cells requires CD28 
costimulation, TCR stimulation, and IL-2. For in vitro studies, the use of activated APC to 
deliver signal 1 and 2 is highly efficient, but for ex vivo Treg expansion to be re-infused into 
animals or patients purity is essential. Currently, the most widely employed tool for Treg 
expansion is the use of beads coated with anti-CD3 and anti-CD28 antibodies (Hoffmann et 
al. 2004; Tang et al. 2004). 
 Given the fact that CD28 superagonists activate T cells without the need of TCR 
ligation, expansion of Treg cells with the use of these antibodies is an interesting approach. 
In fact, Treg cells showed to respond very well to CD28SA stimulation, but they also need IL-
2 for long term expansion (Beyersdorf, Hanke, et al. 2005); it even proved superior than 
                                                
§
 ©LUHDER et al. 2003. Originally published in JEM. doi:10.1084/jem.20021024 
!
 Reprinted from Annals of the Rheumatic Diseases, 64/suppl 4, Niklas Beyersdorf, Thomas Hanke, Thomas 
Kerkau, Thomas Hünig, Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the 
therapy of autoimmune diseases, iv91-5, 2005, with permission from BMJ Publishing Group Ltd. 
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standard costimulation in Treg expansion protocols (Beyersdorf et al. 2006). A schematic 
view of in vivo T-cell activation by CD28SA is depicted in Figure 2 (Hünig 2007). 
 
 
Figure 2. Clonal expansion of Treg cells during a normal immune response and 
by a CD28 superagonist. A. Antigen-driven immune response, where IL-2 produced by 
effector T cells promotes the later expansion of Treg cells. B. Model of a CD28SA 
driven response where both effector and Treg cells are stimulated simultaneously and 
Treg cell expansion is favored (Hünig 2007)•. 
 
1.5. CD28SA preclinical rodent models 
1.5.1. Studies in mice and rats 
Injection of CD28SA in rats (JJ316) (Tacke et al. 1997) or mice (D665) (Dennehy et al. 2006) 
had a very similar effect. Cytokine production at the peak of the response was mainly 
associated with IL-10 production and, to a lesser degree, IL-4, both anti-inflammatory 
cytokines (Rodriguez-Palmero et al. 1999; Hünig 2007). In rats, IL-10 was traced back to be 
produced by Treg cells (CD4+CD25+CTLA-4+FoxP3+) (Beyersdorf, Hanke, et al. 2005; Lin 
and Hunig 2003). Importantly, the proportion of these cells among the CD4 compartment 
increased from an initial percentage of about 5% to 20% in rats, and had a 10 to 20-fold 
increase in mice on day 3 after CD28SA administration, which decreased gradually to normal 
levels by day 10. At the peak of the stimulation, these cells showed to have an activated 
phenotype (CD25highCTLA-4high) and, of importance, a dose dependent suppressive activity 
                                                
• Reprinted from Advances in Immunology, 95, Thomas Hünig, Manipulation of regulatory T+cell number and 
function with CD28+specific monoclonal antibodies, 111-148, 2007, with permission from Elsevier. 
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was measured, which was up to 10-fold higher than Tregs isolated from unstimulated 
animals. Expanded cells had the phenotype of “natural” Treg cells (Lin and Hunig 2003; 
Beyersdorf, Hanke, et al. 2005). 
 When these observations were made several hypothesis arose to try to explain why 
Treg cells were preferentially activated over effector T cells by the superagonistic monoclonal 
antibodies. One was that since Treg cells generated in the thymus recognize self peptides, 
they receive strong signals in the periphery by self-peptide-MHC class II complexes, which 
leads to hyper-phosphorylation of downstream signaling molecules that CD28SA expands, 
and therefore overrule conventional T cell responses (Beyersdorf, Hanke, et al. 2005). 
Another explanation is related to the anti-apoptotic nature of the CD28SA signals, which 
avoids induction of strong pro-apoptotic signals and actively induces anti-apoptotic molecules 
such as BCL-XL, given the fact that Treg cells are highly prone to undergo apoptosis (Kerstan 
and Hunig 2004). 
1.5.2. CD28SA in autoimmune and inflammatory disease models 
Animal studies showed that the Treg cells that are expanded by CD28SA stimulation are 
derived from “natural” Tregs originated in the thymus, which are CD25+, and not from 
converted conventional CD4+ T cells (Lin and Hunig 2003). Naturally occurring Tregs pass 
through a positive selection process in the thymus for autoreactivity, and that makes them 
protective against possible immune reactions against self (Sakaguchi et al. 2006). Based on 
these, CD28SA expansion of Tregs was considered to possibly be a very good approach to 
treat autoimmune or inflammatory diseases, since specificity to antigens related to the 
disease is not necessary (Hünig 2007). 
 To date, treatment with CD28SA has proven effective in a number of animal models 
of autoimmunity or inflammatory diseases; several examples are shown in Table 1. In 
general, they are based on the anti-inflammatory effects of expanded Tregs, either 
therapeutic or preventive, before or after onset of the disease, accomplished by rat (JJ316) 
(Tacke et al. 1995; Tacke et al. 1997) or mouse CD28SA (D665) (Dennehy et al. 2006). 
 Cytotoxic cancer therapies leave the patient with severe lymphopenia which is slowly 
recovered (months to years) (Mackall et al. 1996), contributing to the high incidence of life-
threatening opportunistic infections. CD28SA proved effective in the recovery of lymphopenic 
rats (lethally irradiated, bone marrow-reconstituted) by a dramatic acceleration of T cell 
recovery, mainly CD4 cells, after a single antibody injection (Elflein et al. 2003). 
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Table 1. Examples of rodent models of autoimmune diseases or inflammatory conditions 
where CD28SA treatment has proven its efficacy either as a preventive measure and/or as a 
therapy. 
Strain/species Model Human equivalent References 
Lewis rat Experimental 
autoimmune neuritis 
Guillain–Barré 
syndrome 
Schmidt et al. (2003) 
Lewis, DA rat Experimental 
autoimmune 
encephalomyelitis 
Multiple sclerosis Beyersdorf, Gaupp, et 
al. (2005) 
Wistar rat Adjuvant arthritis Rheumatoid arthritis Rodriguez-Palmero et 
al. (2006) 
Lewis, DA rat Allogeneic liver 
transplantation 
Liver transplantation Urakami et al. (2006) 
BB rat Spontaneous 
autoimmune diabetes 
Diabetes mellitus 
type 1 
Beaudette-Zlatanova et 
al. (2006) 
Lewis, DA rat Allogeneic heterotropic 
heart graft 
Cardiac transplantation Kitazawa et al. (2008) 
Lewis, DA rat Graft-versus-host 
disease (GvHD) 
GvHD Kitazawa et al. (2009) 
Wistar rat Experimental 
glomerulonephritis 
Mesangial proliferative 
glomerulonephritis 
Miyasato et al. (2011) 
Brown-Norway and 
Lewis rat 
Obliterative bronchiolitis 
in allo-orthotopic 
tracheal transplantation 
Obliterative airway 
disease in lung 
transplantation 
Shi et al. (2012) 
C57BL/6, BALB/c 
mouse 
T. brucei and T. 
congolense infection 
African 
trypanosomiasis 
Guilliams et al. (2008) 
C57BL/6 mouse Experimental 
autoimmune 
encephalomyelitis 
Multiple sclerosis Gogishvili et al. (2009) 
C57BL/6 mouse Non-T cell–dependent 
inflammatory arthritis 
Inflammation-induced 
bone loss in 
rheumatoid arthritis 
Zaiss et al. (2010) 
C57BL/6 mouse DSS-induced colitis Inflammatory bowel 
disease 
Chen et al. (2011) 
Abbreviations: T.: Trypanosoma  DA: dark Agouti  DSS: dextran sulfate sodium 
(Hünig 2007)" 
 
 These promising results highlight the potential of Treg cell expansion as an 
immunological therapy, especially because of the fact that knowledge of the autoantigen 
recognized is not required, which is a great advantage for human autoimmune disease 
                                                
" Reprinted from Advances in Immunology, 95, Thomas Hünig, Manipulation of regulatory T+cell number and 
function with CD28+specific monoclonal antibodies, 111-148, 2007, with permission from Elsevier. 
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therapy, and it can be both beneficial on thymic T-cell production as well as Treg 
accumulation. 
 
1.6. TGN1412 – a human anti-CD28 superagonistic monoclonal antibody 
Based on the promising results obtained with numerous animal models on the therapeutic 
potential of CD28SA, a human equivalent was of great interest as a possible therapy for 
several autoimmune diseases. The German Biotech TeGenero generated a set of mouse 
anti-human CD28 mAbs and isolated both conventional and superagonistic antibodies, which 
followed the epitope-function relationship explained in section 1.4.1 (Luhder et al. 2003). One 
of the superagonistic antibodies isolated was developed into fully humanized by genetic 
engineering. Based on the knowledge that IgG4 antibodies have a lower affinity for Fc 
receptors (Presta and Namenuk 2005), and hence might be less likely to recruit cytotoxic 
mechanisms, the superagonistic IgG4 mAb was developed and it was named TGN1412. The 
aim of this antibody was to be used as a treatment of human immune diseases, such as 
rheumatoid arthritis, multiple sclerosis, and B-cell chronic lymphocytic leukemia (Duff 2006). 
1.6.1. TGN1412 preclinical studies – Animal models 
 Preclinical studies in rodent models with the rodent-specific CD28SA showed that 
regulatory T cells were preferentially activated, and hence conferred protection against 
autoimmune and inflammatory diseases. Preclinical safety and toxicity tests were performed 
on cynomolgus monkeys based on the following knowledge: affinity of TGN1412 for CD28 on 
cynomolgus monkeys T cells showed to be very similar to human CD28, a finding which 
correlates with the fact that the extracellular domain of cynomolgus monkeys CD28 showed 
100% identity at the amino acid level compared to the human equivalent. Fc receptor 
interaction of an antibody also influences its biological activity. It was determined that human 
and cynomolgus monkeys FcR are highly conserved, specially the critical motifs involved in 
signal transduction (Hanke 2006). Importantly, cynomolgus monkeys showed no sign of 
cytokine release or toxicity, even at very high doses of 50 mg/kg weight, as reported by 
TeGenero and reproduced by the National Institute for Biological Standard and Control 
(NISBC) study, commissioned by the Expert Commission on Phase I Trials (Duff 2006). 
1.6.2. TGN1412 first-in-man clinical trial 
Based on the promising results obtained in animal models, and the lack of toxicity in 
cynomolgus monkeys, TGN1412 was approved to proceed to a clinical trial. On March 13, 
2006, Parexel International, Northwick Park, London, started the TGN1412 first-in-man 
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clinical trial. Six healthy male volunteers received TGN1412 and two received a placebo. 
Within hours of receiving the TGN1412 infusion the volunteers presented a series of adverse 
effects that progressed to multi-organ failure. They presented a systemic inflammation 
caused by a cytokine release syndrome (CRS) also termed “cytokine storm”, that started with 
high levels of the proinflamatory cytokine TNF-!, followed by IFN-# and several other 
cytokines. Volunteers were transferred to an intensive care unit, where the symptoms were 
successfully treated with high dose corticosteroids (Suntharalingam et al. 2006). 
1.6.3. Current knowledge on CD28 superagonists – After the CRS 
After the unexpected and shocking outcome of the TGN1412 first-in-man trial the scientific 
community was in desperate need of answers. Why wasn)t this foreseen in animal and/or in 
vitro models? Why did the mechanisms observed in rodent models, namely Treg cell 
proliferation and activation, failed to protect the human volunteers? By now it is clear that the 
cell type that mainly released the proinflammatory cytokines were the effector memory T cells 
(Eastwood et al. 2010). These cells are mostly located in tissues and respond very rapidly to 
secondary stimulation. Laboratory animals are kept under clean conditions, so they have 
very few numbers of memory cells due to low exposure to infections, so the balance of the T 
cell compartment is different than in humans, which accumulate a great number of memory 
cells throughout their life (Hünig 2012). Gogishvili et al. (2009) showed in a mouse model that 
Treg cell depletion previous to CD28SA (D665) treatment leads to considerable cytokine 
release and, importantly, it could be controlled by the use of corticosteroids, which in turn did 
not affect Treg cell expansion and function. 
 Regarding cynomolgus monkeys, despite many attempts to explain the non-toxic 
effect of TGN1412, the reason was surprisingly simple. It was recently found that the CD4+ 
effector memory cells do not express CD28, which is the cell type that responds to TGN1412 
stimulation (Eastwood et al. 2010). 
 Finally, human PBMC in vitro assays failed to predict the cytokine storm observed. To 
date several approaches have been made, which will be discussed later, both to find an in 
vitro method that allows to predict the CRS induced by TGN1412, and to explain the 
differences between the in vitro and the in vivo situation. In this study, an in vitro assay was 
developed that allowed both to find a plausible explanation on why circulating PBMC did not 
respond to soluble TGN1412 stimulation, and to improve the current PBMC in vitro assays 
for immunological drug testing. 
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2. Introductory statement on contributions and previous publication 
This thesis was conducted in the research laboratory of Prof. Thomas Hünig (Institute for 
Virology and Immunobiology, University of Würzburg). Experimental procedures of this PhD 
project were performed by myself, with technical assistance from Susanne Berr - unless 
stated otherwise. Shin-Young Na (Postdoc, Prof. Hünig)s group) performed confocal analysis 
of human lymph node sections, and Elita Avota (Postdoc, Prof. Schneider-Schaulies) group) 
of human PBMC. Manuela Battaglia (San Raffaele Diabetes Research Institute, Milan, Italy) 
obtained, stimulated, and measured proliferation of human lymph node cells. Ineke ten 
Berge (Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands) 
provided paired human lymph node and PBMC samples. The bulk of this research was 
originally published in Blood. Authors: Paula S. Römer, Susanne Berr, Elita Avota, Shin-
Young Na, Manuela Battaglia, Ineke ten Berge, Hermann Einsele, Thomas Hünig. Title: 
Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing 
cytokine release by CD28 superagonist TGN1412. Blood. 2010;118:6772-6782. © the 
American Society of Hematology. 
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3. Methods 
3.1. Cell isolation and preparation 
3.1.1. Human PBMC isolation 
Human PBMC were obtained either from healthy donors as a byproduct of platelet 
concentrates from leukoreduction system chambers (LRS-C) (7-9 mL), and filled up with 
Versene to 60 mL; or directly from heparinized venous blood. PBMC were separated by 
density gradient centrifugation using Lymphocyte Separation Medium and Leucosep tubes, 
and washed twice with ice-cold balanced salt solution (BSS) / 0.2% bovine serum albumin 
(BSA). 
3.1.2. Human lymph node cells 
Lymph nodes were obtained from two sources, one from the pancreas of non-diabetic brain-
dead multi-organ donors, from the San Raffaele Hospital, Milan, Italy. 
Alternatively, lymph nodes were collected from the para-iliac region of renal transplant 
recipients, received from the Academic Medical Center, Amsterdam, Netherlands. Paired 
peripheral blood samples were collected before the transplantation procedure. Cells were 
frozen in IMDM supplemented with 10% DMSO, 20% FCS, penicillin, streptomycin and 
0.00036% "-mercaptoethanol. 
3.1.3. Cell culture 
Cells were cultured under sterile conditions in a humidified incubator at 37 ºC, 5% CO2 in AB 
medium. 
3.1.4. Freezing and thawing 
Cells were cryopreserved at -140°C. 5x107 cells in 1 mL of freezing medium in cryotubes, 
kept at -80°C in a pre-cooled (4°C) “Mr. Frosty” Cryogenic Freezing Container filled with 
isopropanol for 24h, then transferred to a -140°C freezer. 
 Vials where thawed in a 37°C water bath until there was a pea-sized pellet of ice 
remaining. Cell suspensions were then transferred to a correspondingly labeled 50 mL 
Falcon tube containing 8 mL of pre-warmed AB medium with DNase (5 U/mL), and incubated 
for 10 min at room temperature (RT); centrifuged and washed once more with AB medium, 
resuspended in AB medium and left 20 min at RT, then kept on ice until use. 
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3.1.5. Depletion and isolation of cell subsets 
CD4+ T cell isolation from human PBMC was performed using the CD4+ T Cell Isolation Kit II 
from Miltenyi Biotec, following the manufacturer)s instructions, and for monocytes, the 
Monocyte Isolation Kit II from Miltenyi Biotec was used following the manufacturer)s 
instructions; with the only modifications of using BSS/BSA instead of their recommended 
buffer, in both cases. MACS LS columns were used for positive or negative selection, and 
MACS LD columns for cell depletion.  
 For cell subset depletion, anti-PE microbeads, anti-FITC microbeads, and goat anti-
mouse IgG microbeads were used accordingly, following the manufacturer)s instructions. 
PBMC were stained with CD19-PE, CD83-PE, CD14-FITC, or Tü39 (anti-HLA-DR,DP,DQ). 
Cells expressing CD19, CD83 and CD14 where depleted simultaneously. In this case, PBMC 
were stained with CD14-FITC, CD19-PE and CD83-PE. CD19 and CD83 positive cells were 
depleted using anti-PE microbeads, and CD14+ cells were subsequently depleted using anti-
FITC microbeads. 
 
3.2. Stimulation assays – RESTORE protocol 
The optimized “RESTORE” protocol was done by preculturing PBMC at a high cell density of 
1.5x107 cells in 1.5 mL (1x107 cells/mL) in 24 well suspension culture plates for 2 days, in a 
humidified incubator at 37°C, 5% CO2. After this preculture period, cells were harvested 
using ice-cold AB medium, washed, and prepared for stimulation.  
Cells stimulated at 1x106 cells/mL in 96-well flat bottom plates (200 µL/well, 2x105 
cells). GMP-grade TGN1412 and clinical grade OKT3 were used. 
During the optimization process, cells were precultured at low cell density (1x106 
cells/mL), and several preculture times were performed. 
 
3.3. Western blotting 
3.3.1. Cell lysis 
Cells were lysed in lysis buffer and incubated on ice for 1h, vortexing for 5 sec. medium 
speed every 5 min. The lysate was centrifuged at 20,000 x g at 4°C for 10 min.  
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3.3.2. Pre-clearing of cell lysate 
The cell lysate was pre-cleared by mixing it with 30 µL of 50% protein-G sepharose, and 
incubated 30 min in rotation at 4°C. Repeated 2x if the lysate was prepared from cells 
expressing immunoglobulins. 
3.3.3. SDS-polyacrylamide gel electrophoresis  
Protein extracts were separated on 12.5-15% SDS polyacrylamide gels under reducing 
conditions (boiled 10 min, 96°C with 1x SDS reducing sample buffer). The separating gel mix 
was prepared, poured into the gel apparatus, and overlaid with water. After the gel 
polymerized, the water was decanted and the stacking gel was poured. Protein samples 
were loaded, and ran in 1x SDS PAGE running buffer.  
3.3.4. Western Blot  
Proteins from the SDS-PAGE gel were blotted to a nitrocellulose membrane at 50 mA, 500 V 
for 2h at 4°C. The membrane was washed with H20 for 5 min., then with methanol 5 min., 
and incubated with 5% milk powder in PBS-0.1% Tween for 1h at RT on a rocker platform.  
The nitrocellulose membrane was incubated with the primary Ab diluted in 1% milk 
powder in PBS-0.1% Tween, O/N at 4°C. The membrane was washed 6x with PBS-0.1% 
Tween for 5 min each time, on the rocker platform at RT, then incubated with a horseradish-
peroxidase-conjugated secondary Ab for 1-2h, on the rocker platform at RT. After incubation, 
the membrane was washed again 6x with PBS-0.1% Tween for 5 min each time, on the 
rocker platform at RT, then treated with enhanced chemiluminescent substrate and 
developed in the dark box (LAS-3000).  
 
3.4. Cell proliferation assays 
3.4.1. 3H-thymidine incorporation 
After cell stimulation, proliferation was measured as radioactivity incorporated from day 2 to 3 
from 3H-thymidine (1 µCi per well) into DNA, using a Liquid Scintillation Counter. Results are 
expressed as counts per minute (cpm). 
3.4.2. Ki67 staining 
Cells were stimulated for 3 days, and cold harvested. PBMC were surface stained, washed 
once with FACS buffer, then incubated with fixation/permeabilization buffer (eBioscience) for 
30 min. in the dark in order to fix and permeabilize the cells allowing intracellular (nuclear) 
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staining, washed 1x with FACS buffer, 1x with Perm/Wash, and incubated with anti-Ki67 
antibody diluted in Perm/Wash for 30 min. at 4°C, in the dark. Washed with FACS buffer and 
resuspended in either FACS buffer for immediate analysis or fixed with 2% PFA until analysis 
(maximum 1 day). Kept at 4°C. 
 
3.5. Cell dissociation experiment 
Lymph node cells were prepared at 1x106 cells/mL in AB medium, and either stimulated 
immediately or placed in a humidified incubator at 37°C for two or four hours, in a 50 mL 
Falcon tube without the lid to allow gas exchange. The cells were gently mixed every 20 min. 
to keep them in suspension. 
 
3.6. Transwell assay 
Freshly isolated PBMC were placed in the lower compartment of the transwell system in low 
cell density (1x106 cells/mL), while high-cell density PBMC (1x107 cells/mL) from the same 
donor were placed in the upper compartment of the transwell insert, therefore allowing 
exchange of soluble factors, but not of cells. Controls were included with only low or high-
density cells. The system was incubated for two days at 37°C, 5% CO2. 
 Cells were recovered from the wells with or without the transwell insert and stimulated 
at 1x106 cells/mL in 96-well flat bottom plates (200 µL/well) for 24 h at 37°C. Cell culture 
supernatant was taken and cytokine levels measured by Cytometric Bead Array (CBA). 
 
3.7. Flow cytometry (phenotyping) 
Cells were washed with FACS buffer, resuspended in the antibody preparation, and 
incubated for 20 min. at 4°C. Washed with FACS buffer and resuspended in either FACS 
buffer for immediate analysis or fixed with 2% PFA until analysis (maximum 1 day). Kept at 
4°C. 
 
3.8. Cytokine release quantification 
Cytokine release was evaluated by three methods: Cytometric Bead Array (CBA), enzyme-
linked immunospot assay (ELISPOT) or by intracellular cytokine staining. The first two were 
performed following the manufacturers instructions. 
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3.8.1. Intracellular cytokine staining 
Brefeldin A was added on the last four hours of a 6 or 16h stimulation in order to block the 
cytokine secretion. Cells were surface stained, washed once with FACS buffer, then 
incubated with fixation/permeabilization buffer (BD) for 30 min. in the dark in order to fix and 
permeabilize the cells for intracellular (cytoplasmic) staining, washed 1x with FACS buffer, 1x 
with Perm/Wash, and incubated with an antibody directed against the cytokine of interest, 
diluted in Perm/Wash for 30 min. at 4°C, in the dark. Washed with FACS buffer and 
resuspended in either FACS buffer for immediate analysis or fixed with 2% PFA until analysis 
(maximum 1 day, 4°C). 
3.8.2. Responding cell subset determination 
To determine which subset of the memory CD4+ T cell compartment responds to TGN1412, 
purified CD4+, CD4+CCR7+, or CD4+CCR7- T cells (MACS separation) were obtained. CD4+ T 
cells were isolated using the CD4+ T Cell Isolation Kit II, following manufacturers instructions. 
Cells were then surface stained with !-human CCR7-FITC antibody, positive and negative 
cells were separated using !-FITC microbeads and an LS column. Positive cells were 
passed again through an LS column, and negative cells through an LD column, to improve 
the purity of the obtained fractions. 
 CD4+, CD4+CCR7+, and CD4+CCR7- T cells were CFSE labeled, mixed with intact 
PBMC in high cell density (1x107 cell/mL) by including 20% of CFSE labeled cells, and 
incubated for two days at 37°C, 5% CO2. Cells were harvested, placed in low cell density 
(1x106 cell/mL), stimulated for 6 hours with 1 µg/mL TGN1412 or OKT3. Brefeldin A was 
added at the beginning of the stimulation. PBMC were cold harvested, washed, and stained 
for intracellular TNF. Gates were done in CFSE+ cells. 
 
3.9. CFSE labeling 
Wash cells 2x with 10 mL PBS, resuspend in CFSE 1:25,000 at 1x107 cells/mL. Incubate for 
5 min., RT, in the dark. Centrifuge for 5 min., 300 x g, 4°C, and wash 2x with cold RPMI-1640 
medium with 10% fetal calf serum (FCS) (RPMI-10). Resuspend in AB medium. 
 
3.10. Confocal microscopy 
Paraffin embedded human lymph node sections (3 µm) were deparaffinized, boiled in citrate 
buffer, and blocked with PBS / 10% BSA.  
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Human PBMC kept in ice-cold PBS / 0.02% sodium azide were allowed to adhere to poly-
lysine-coated glass slides, fixed with paraformaldehyde and permeabilized with 0.1% Triton 
X-100 for 5 min. 
 
3.11. Statistical analysis 
To evaluate statistically significant differences, the Wilcoxon signed rank sum test, paired t 
test, unpaired t test, and two-way ANOVA were used. In all cases a P value less than 0.05 
was considered as significant. 
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4. Results  
4.1. PBMC response to soluble TGN1412 
In order to study why the cytokine storm elicited by TGN1412 was not predicted by in vitro 
assays, the response to soluble TGN1412 was evaluated. Initially, freshly isolated circulating 
human PBMC were used in the stimulations. As a positive control, the anti-CD3 mAb 
Muromonab (OKT3) was used, which is known to generate a strong cytokine release in vivo 
(Abramowicz et al. 1989B; Chatenoud et al. 1990). Both reagents were added at 1 µg/mL, 
which is in the range of the estimated concentration reached in the blood of the volunteers 
during the TGN1412 Phase I Clinical Trial (Waibler et al. 2008). 
 Cell culture supernatant was collected after 24 h stimulation, and cytokine levels were 
determined (TNF, IL-2 and IFN-#) by Cytometric Bead Assay (CBA). These cytokines were 
highly elevated in the blood of the healthy London trial volunteers after TGN1412 infusion 
(Suntharalingam et al. 2006). Figure 3A shows that freshly isolated PBMC respond by 
cytokine release to soluble OKT3, but not to TGN1412, as it has been previously reported 
(Duff 2006; Stebbings et al. 2007). 
 After failing to reproduce in vitro the cytokine storm generated by TGN1412 in vivo, 
there was an unexpected breakthrough. In one opportunity isolated PBMC were kept for two 
days in the incubator at a high cell density, while waiting for a missing reagent. When the 
stimulation assay was repeated with these cells, TGN1412 induced a high cytokine release 
of comparable magnitude as the one elicited by OKT3 (Figure 3B) (Römer et al. 2011). This 
methodology was termed “RESTORE” protocol, for RESetting T-cells to Original REactivity. 
 The results are highly reproducible (over 150 healthy donors). Figure 3C shows 
results obtained from the first 22 individuals tested. There is a consistent induction of 
TGN1412 reactivity by preculture, whereas fresh PBMC do not respond to stimulation. This 
phenomenon of an “in vitro cytokine storm” resembles the in vivo situation, and is 
comparable to the OKT3 response (Goldman et al. 1989). 
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Figure 3. Human PBMC cytokine release response to soluble TGN1412. A. Fresh and B. 
precultured PBMC are compared by their cytokine release profile in response to TGN1412 or 
OKT3. Data are mean ± SD of triplicate samples. C. Compilation of the results obtained from 
22 healthy individuals. Cytokines determined by CBA in cell culture supernatant after 24h 
stimulation with 1 µg/mL TGN1412 or OKT3. Wilcoxon signed rank test: *P<.05, **P<.005, 
***P<.0001. (-) represents unstimulated cells. 
 
 TGN1412 acts as a mitogen on precultured PBMC, with comparable strength to 
OKT3 (Figure 4A). In contrast, fresh PBMC did not proliferate when stimulated with 
TGN1412, but did with OKT3 stimulation, in accordance with the results obtained with 
cytokine release as a read-out (Figure 3). The response of precultured PBMC elicited by 
TGN1412 can be titrated and is of comparable magnitude to the response to OKT3, as 
shown by TNF release in Figure 4B. There is a detectable TGN1412 response already at 
0.06 µg/mL, which is equivalent to , 1% receptor occupancy (Waibler et al. 2008). At 1 
µg/mL the maximum biological response is achieved, which is now known to represent 45 to 
80% of occupied CD28 molecules (Waibler et al. 2008). 
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Figure 4. Properties of the RESTORE response to TGN1412. A. 
Proliferative response of fresh and high-density precultured PBMC to 
stimulation with 1 µg/mL TGN1412 or OKT3. B. TNF in cell culture 
supernatants after 24h stimulation to titrated amounts of TGN1412 and 
OKT3. Data are mean ± SD of triplicate samples. 
 
4.2. Optimization of the RESTORE protocol 
In order to determine the optimal preculture time for the RESTORE protocol, cells were 
stimulated either fresh or kept in the incubator at 1x107 cells/mL for 24 or 48 h (Figure 4B). 
The best proliferative response was obtained after 48 h of high-density PBMC preculture. 
Preculture of PBMC is performed at a 10-fold higher cell density than the concentration used 
in standard PBMC assays. Preculture at high (1x107 cells/mL) but not at low (1x106 cell/mL) 
cell density rendered PBMC reactive to TGN1412 stimulation, suggesting the requirement for 
cell contact (Figure 5B). Further increase in cell density or pre-incubation time did not 
improve the response (not shown). 
 To find the optimal conditions for the preculture, tissue and suspension culture plates 
were compared. PBMC were placed in high cell density for 2 days in each plate type, and 
stimulated as described previously. As shown in Figure 5C, a slightly better response is 
obtained when suspension culture plates are used during the preculture, although tissue 
culture plates also allow the acquisition of TGN1412 reactivity. 
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Figure 5. Optimization of the RESTORE protocol. A. Proliferative response of precultured 
PBMC to 1 µg/mL TGN1412 B. TNF release in cell culture supernatants after 24h stimulation 
with 1 µg/mL TGN1412 from low or high-density precultured PBMC. Data are mean ± SD of 
triplicate samples. C. Comparative TNF release response to 1 µg/mL TGN1412 between PBMC 
precultured at a high cell density in either tissue culture (TC) or suspension culture (SC) plates. 
Data from single values of two independent experiments ± SD is shown. 
  
 Based on these findings, optimal RESTORE preculture conditions were used in all 
subsequent experiments, 
 
Preculture:  
Time: 2 days 
Cell density: 1x107 cells/mL or 2x106 cells/cm2 
Plate type: Suspension culture plates 
Medium: AB medium 
  
Stimulation:  
TGN1412: 1 µg/mL 
OKT3: 1 µg/mL 
Cell density: 1x106 cells/mL or 2x105 cells/cm2 
 
4.3. Loss of suppression vs. gain of function after high-density preculture 
There could be several explanations for the acquisition of TGN1412 reactivity. One of 
the hypotheses on why PBMC are suddenly responding after a two-day preculture period at a 
high cell density is that a specific cell subset is changing, i.e. regulatory T cells dying or 
enrichment of a subset. To verify if this is the case, fresh and precultured PBMC were 
stained for a variety of cell markers. Figure 6 shows that there is no remarkable change in 
cell subset composition after the preculture period. Dendritic cells (CD83+) remained under 
1% before and after preculture (not shown). 
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Figure 6. Cell subset composition of fresh and precultured PBMC. A. Fresh and precultured 
PBMC were stained surface or intracellularly (FoxP3) with the given antibodies. Each line represents 
a different blood donor. Gating strategy is shown in the Y-axis. 
 
 To further verify that the preculture effect was not due to a loss of suppression, but to 
a gain of function, fresh and precultured cells from the same donor were mixed at different 
ratios. TNF release measured after TGN1412 stimulation was directly proportional to the 
fraction of precultured cells (Figure 7), showing that fresh cells did not suppress the 
response, which suggests that the effect of 2-day high density preculture is not due to a loss 
of suppression, i.e. Tregs losing their suppressive capacity or missing anti-inflammatory 
cytokines. It rather seems to be due to a gain of function of the precultured PBMC, which 
renders them TGN1412 reactive. 
 
 
Figure 7. TNF release of fresh and precultured PBMC 
mixed at different ratios during stimulation. TNF 
concentrations measured in cell culture supernatants by 
CBA after 24h stimulation with 1 µg/mL TGN1412. Data 
are mean ± SD of triplicate samples. 
 39 
 
4.4. Properties of the RESTORE response of PBMC to soluble TGN1412 
TGN1412 binds to CD28 which is expressed on T cells, but which subset of T cells 
respond to TGN1412 stimulation after preculture? In Figure 8 we can clearly see that 
production of TNF and IFN# in response to TGN1412 is restricted to CD4+ memory cells 
(CD45RO+), a finding also shown by Eastwood et al. (2010). There was a significant positive 
correlation between cytokine production and the percentage of CD4+CD45RO+ cells (N = 15, 
Spearman r = 0.70, P = .0039). 
 
 
Figure 8. Intracellular cytokine staining of precultured PBMC. Cells were stimulated 
for 16h with 1 µg/mL TGN1412 or OKT3. For optimal resolution, a donor with a 
particularly high TNF release was chosen. 
 
Recently published work using plastic-immobilized TGN1412 suggests that the CD4 
effector memory T cells (CD45RO+CCR7-) are the main cytokine producers to TGN1412 
stimulation (Eastwood et al. 2010). In Figure 9 this finding could be corroborated (see 
method in section 3.8.2). Of the CD4+ T cells added to the preculture, 2.3% released TNF in 
response to TGN1412. When CD4 effector memory T cells (CCR7-) were enriched the TNF 
responder cells to soluble TGN1412 stimulation increased considerably (9% responder cells), 
while in contrast central memory T cells (CCR7+) were only 0.5% (Figure 9). This finding 
reveals that the main source of proinflammatory cytokines to TGN1412 stimulation are the 
CD4 effector memory T cells. 
 To determine whether the proliferating cells are the same cell type that releases the 
cytokines, an intracellular Ki67 staining was performed. As shown in Figure 10, proliferating 
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cells to soluble TGN1412 stimulation are indeed of the memory cell compartment 
(CD4+CD45RO+), the same cell type producing cytokines (Figure 8). 
 
 
Figure 9. TNF release by effector memory T cells from precultured PBMC in 
response to TGN1412. Purified CD4+ T cells, and either CCR7+ or CCR7- were 
separated and CFSE labeled. Mixed 1:5 with intact PBMC in high cell density and 
incubated for 2 days, 37°C, 5% CO2. Stimulation was done for 6h with 1 µg/mL 
TGN1412 or OKT3. Gated on CD4+ T cells. 
 
 
 
Figure 10. Proliferation of high density precultured PBMC in response to 
TGN1412 and OKT3 determined by Ki67 staining. Intact PBMC were 
stimulated with 1 µg/mL TGN1412 or OKT3 for 3 days. Gated on lymphocytes. 
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4.5. Cellular interactions during high-density preculture 
Acquisition of TGN1412 reactivity by preculture requires high cell density (Figure 5B). In 
order to confirm if cell contact is indeed necessary, a transwell assay was employed (section 
3.6). In this system soluble factors can be exchanged between low density and high-density 
cells through a semipermeable membrane, which cells cannot cross. 
 The low density PBMC precultured in the presence of high density PBMC separated 
by a semipermeable membrane did not respond to TGN1412 (Figure 11), meaning that a 
soluble factor is not sufficient for the acquisition of reactivity. This confirms the need of cell-
cell contact for the acquisition of TGN1412 reactivity. 
 
 
Figure 11. Cell contact is required for acquisition of TGN1412 reactivity. Cytokine 
release upon TGN1412 stimulation (24 h, 1 µg/mL) after preculture at high (107 cells/mL) 
and low (106 cells/mL) cell density, or at low cell density with a transwell insert containing 
high-density PBMC (106 / 107). Measured by CBA. Data are mean ± SD of triplicate 
samples. 
 
 To study the effect of high-density culture on the T cells it is important to characterize 
the interactions and effects that happen within the system. It has been shown that CD28SA 
require weak or “tonic” TCR signals in order to elicit a response (Dennehy et al. 2007; Levin 
et al. 2008); and priming of the TCR complex of mouse lymph node CD4 T cells can occur by 
cellular adhesion (Randriamampita et al. 2003), or by MHC scanning of APC within the organ 
(Stefanova, Dorfman, and Germain 2002; Hochweller et al. 2010). These signals promote the 
preassembly and phosphorylation of proximal intracellular signaling proteins of the TCR 
complex, keeping the cells in an optimal state of sensitivity, allowing them to respond faster 
and more efficiently to a foreign peptide (Stefanova, Dorfman, and Germain 2002). 
Importantly, mouse CD4 T cells lose this quality when entering the blood stream, because 
they lack cell contacts (Stefanova, Dorfman, and Germain 2002). 
 Based on these previous findings, a possible explanation for the unresponsiveness of 
circulating human PBMC to TGN1412 is that they have lost their “primed” status, which can 
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be recovered by allowing cell-cell interactions, i.e. MHC scanning. Placing circulating PBMC 
in high cell density allows the recovery of this sensitive state. 
 One of the features of the assembly of the TCR complex and the immunological 
synapse involves phosphorylation of tyrosine residues in proteins involved in the signal 
transduction cascade downstream of the TCR. Therefore studying the tyrosine 
phosphorylation status of the cells in the RESTORE system could shed a light on the 
mechanism behind the acquisition of TGN1412 reactivity by preculture. 
 The distribution of the TCR component CD3 molecule and of tyrosine-phosphorylated 
proteins in human lymph node sections was studied, as well as in fresh and high density 
precultured PBMC. Figure 12 (experiment by Dr. Shin-Young Na) shows a clear co-
localization of CD3 with phosphotyrosine (pTyr) staining (overlay) in the human lymph node 
section. CD3 is not evenly distributed in the cell surface, but in a polarized fashion, while 
CD45 (common leukocyte antigen) shows an even distribution (control staining) and, more 
importantly, does not co-localize with pTyr. 
 
 
Figure 12. Colocalization of CD3 with tyrosine-phosphorylated proteins in 
human lymph node sections. Human lymph node sections were co-stained with 
anti-CD3 mAb (red) and anti-phosphotyrosine (pTyr, green). Anti-CD45 mAb was 
included as a negative control. Appropriate isotype controls were included. 
Experiment performed by Dr. Shin-Young Na.  
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In contrast, freshly isolated PBMC show a homogeneous distribution of CD3 on the 
cell surface, and barely any tyrosine phosphorylation on the T cells, as compared to non-T 
cells (Figure 13, experiment by Dr. Elita Avota). Precultured PBMC, on the other hand, show 
a remarkably high and polarized tyrosine phosphorylation, which co-localizes with CD3, 
forming cap-like structures. These structures suggest the formation of a partially activated 
TCR complex in the lymph node, and tyrosine phosphorylation after the 2-day preculture at a 
high cell density, as seen in the human LN sections (Figure 12), suggesting that the T cells 
have returned to tissue-like conditions. 
 
 
Figure 13. Colocalization of CD3 with tyrosine-phosphorylated proteins in 
fresh and high density precultured human PBMC. Human lymph node 
sections were co-stained with anti-CD3 mAb (red) and anti-pTyr (green). An 
isotype control for pTyr was included. For statistical analysis of colocalization, see 
Figure 14. Experiment performed by Dr. Elita Avota.  
 
 Statistics and colocalization coefficients were calculated for the confocal microscopy 
images of fresh and precultured PBMC (Figure 14, analysis by Dr. Elita Avota). On freshly 
isolated cells, pTyr positive cells were not of T cell origin (CD3-) (Figure 14A). In contrast, 
84% of the T cells analyzed in precultured PBMC (150 cells) showed significant 
colocalization of CD3 and pTyr on the cell surface (Figure 14B). 46% of the cells showed a 
high colocalization coefficient (above 0.65). 
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Figure 14. Statistical analysis and colocalization coefficient of 
CD3 and pTyr in fresh and precultured PBMC. Representative 
pseudocolored scatter plots from individual cells are shown. A. 
Representative CD3+ cell (left panel) of 150 analyzed. B. 
Representative examples and frequencies of T cells showing low, 
intermediate, or high CD3-pTyr colocalization values. Analysis 
performed by Dr. Elita Avota. 
 
 Western blots were performed to biochemically characterize fresh and precultured 
PBMC. As a primary antibody 4G10 was used, which is an anti-phosphotyrosine antibody. In 
high-density precultured cell lysates several phosphorylation events were detected. By this 
method it is not clear which ones belong to T cells. A band that presented consistent and 
strong phosphorylation in HDC cells and not in fresh PBMC presented a molecular weight of 
around 18 kD. The native form of CD3 has a molecular weight of 16-18 kD, but when it 
becomes phosphorylated it increases the molecular weight up to 21 kD. A control was 
performed using an !CD3-$ antibody (CD247), raised against amino acids 36-54 mapping 
within an N-terminal domain of CD3-$ of human origin. This control showed the same level of 
CD3-$ expression for both fresh and precultured cells, with a 17 kD band (not shown). In 7 
independent experiments a band with a molecular weight higher than 17 kD appeared in 
precultured cells lysates, which was never present in fresh PBMC lysates (Figure 15). The 
observed band might correspond to the phosphorylated CD3-$ chain, which when 
phosphorylated gives a typical molecular pattern with multiple bands ranging from 16-21 kD, 
representing the varying degrees of phosphorylation of the six cytoplasmic tyrosine residues 
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of the $ chain (Irving and Weiss 1991; van Oers 1999). The capacity of CD3-$ to undergo 
multi-site tyrosine phosphorylation has been thought to constitute a molecular processor 
capable of translating the different types of TCR interactions into discrete phosphoforms and 
possibly distinct outcomes in the T cell response (Kersh, Shaw, and Allen 1998; Ardouin et 
al. 1999). Following this model, differential TCR signaling should depend on the integrity of 
the CD3-& ITAMs, therefore tonic signals through TCR-MHC interactions might give out a 
distinct pattern of tyrosine phosphorylation that makes T cells more sensitive to TCR 
activation. This observation was not further investigated, but it would be extremely interesting 
to study further the differences between fresh and precultured PBMC using biochemical 
tools. 
 
 
Figure 15. Western blot of fresh and precultured PBMC 
lysates. Fresh (F) and precultured (P) PBMC lysates from two 
different donors. Developed with 4G10 antibody (anti-pTyr). 
15% polyacrylamide gel. Reducing conditions. One of 5 
independent experiments is shown. 
 
 To determine whether the acquisition of TGN1412 reactivity depends on HLA 
scanning by the TCR, blocking mAb recognizing all HLA class I or class II molecules were 
added during the preculture. After 2 days the antibodies were washed out and the cells were 
stimulated with TGN1412 for 24 h. Figure 16A shows that intact antibodies efficiently 
prevented the acquisition of TGN1412 reactivity, as seen by decreased cytokine release. To 
avoid possible effects of the Fc portion of the blocking antibodies (negative signaling, FcR-
mediated cytotoxicity) Fab fragments were generated. A strong reduction in the acquisition of 
TGN1412 reactivity was again observed (Figure 16B). 
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 Since HLA recognition is important for sensitization of T cells to TGN1412, blockade 
of intracellular signaling proteins involved with the TCR complex during the high-density 
preculture should also have a negative effect. For this purpose, PP1 was used, which is an 
inhibitor of Src family kinases with selectivity for Lck. As expected, when PP1 was included 
during the subsequent stimulation assay there was a complete blockade of the response 
(Figure 17), since it is known that the CD28SA response depends on Lck (Bischof et al. 
2000). Importantly, inclusion of PP1 during the 2-day high density preculture also strongly 
reduced the subsequent TGN1412 reactivity, while a brief pulse before harvest had no effect 
(wash out control; Figure 17). 
 
 
Figure 16. Role of HLA recognition in TGN1412-reactivity acquisition 
during high-density preculture. !HLA class I clone W6/32 and !HLA 
class II clone Tü39 antibodies were used either A. intact or B. as Fab 
fragments. Stimulation with 1 µg/mL TGN1412 for 24h. Cytokines 
measured in cell culture supernatant by CBA. Two different donors are 
shown. Data are mean ± SD of triplicate samples. 
 
 In the mouse lymphoid organs and other tissues, MHC scanning by T cells induces a 
basal activation level that allows subsequent responsiveness upon encounter with foreign 
antigens. This basal activation is provided by T-cell scanning of MHC molecules on the 
 47 
 
surface of dendritic cells (Hochweller et al. 2010). In order to determine the cells involved in 
this process in the RESTORE protocol, distinct cell populations were depleted from human 
PBMC prior to preculture (Figure 18). 
 
 
Figure 17. LcK inhibitor PP1 affects acquisition of 
TGN1412 reactivity during preculture. PP1 20 µM 
added during preculture or into stimulation. Precultured 
PBMC stimulated with 1 µg/mL TGN1412. TNF 
measured in cell culture supernatant by CBA. Two-way 
ANOVA: P<.0001. Data are mean ± SD of triplicate 
samples. 
 
 
Figure 18. Depletion of cell subsets from fresh human PBMC. Dot plots 
showing cells before and after depletion. Depletion efficiency of 
CD14/CD19/CD83 simultaneously was 99%. 
 
Reinstatement of T-cell reactivity by preculture depends on the presence of 
monocytes, the predominant APC in PBMC (Figure 19). The addition of 50% low-density 
precultured PBMC (not functionally mature, Figure 5) to the depleted group shows that the 
effect observed is due to lack of monocytes during the preculture supporting the idea of the 
need of T-cell–monocyte interactions for the restoration of T cell reactivity. 
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Figure 19. Acquisition of TGN1412 reactivity requires the presence of monocytes 
during high-density preculture. Before preculture at high cell density, PBMC were 
depleted from the cell subsets indicated with (-). The group "All" refers to undepleted 
PBMC. In the lower panel unseparated PBMC precultured at low cell density (LDC) were 
added as a source of the depleted subset at a 1:1 ratio during stimulation. HDC indicates 
high-density cell cultures; LDC, low-density cell cultures; DC, dendritic cells; and MHC II+ 
major histocompatibility complex class II-positive cells. Data are mean ± SD of triplicate 
samples. 
 
Mouse hyporesponsive T cells are able to quickly (30 min) regain their antigen 
sensitivity when co-cultured with DC (Hochweller et al. 2010). In contrast, in the RESTORE 
protocol, T cells take 2 days to regain tissue-like sensitivity (Figure 5). Since APC are 
involved in this process, the time requirement suggests that monocytes are not functionally 
mature, and therefore not able to provide T cells with the interactions needed to acquire a 
sensitive status.  
To test if monocytes which had matured in high-density precultured PBMC would 
allow fresh T cells to respond, a 1:1 co-culture of fresh and HDC PBMC from the same donor 
was performed. Fresh cells were CFSE labeled in order to trace them back in the co-culture. 
The surface expression of CD69 after 16 h stimulation was used as readout, which provides 
information about early activation of T cells. Stimulation with either TGN1412 or OKT3 
prompted the surface expression of CD69 on HDC cells when stimulated separately, but as 
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expected TGN1412 failed to do so on fresh PBMC (Figure 20). On the other hand, CD4+ T 
cells from fresh PBMC in the presence of HDC PBMC  (co-culture) expressed CD69, 
although to a lower extent than the HDC portion. 
 
 
Figure 20. CD69 expression by fresh PBMC in response to stimulation 
with soluble TGN1412 in the presence of HDC PBMC. Fresh (CFSE 
labeled) and high-density precultured PBMC were stimulated for 16h at low 
density, either separately or in co-culture (1:1), with 1 µg/mL TGN1412 (blue) 
or OKT3 (red). T cell activation was determined by CD69 surface staining, 
gated on CD4+ T cells. 
 
The kinetics of this response were studied in more detail. For this purpose, fresh and 
HDC PBMC were mixed 1:1 in high cell density and left for 0, 2 or 4 hours before dilution and 
addition of soluble TGN1412 (Figure 21). CD69 surface expression was assessed after 2 h of 
stimulation. The percentage of CD4+ memory T cells from freshly isolated PBMC expressing 
CD69 in response to subsequent TGN1412 stimulation increased already after two hours of 
joint preculture. During the 4 h of high-density co-culture the percentage of responding fresh 
cells doubled from 5% to 10%, while responding precultured cells remained around 20%. 
 In conclusion, the presence of HDC cells allowed a percentage of fresh cells to get 
activated in response to TGN1412 stimulation. This suggests that the cellular environment in 
the 2-day high density precultured cells made the fresh CD4+ memory T cells responsive, but 
to a lower extent than the CD4 memory cells from HDC (Figure 21). 
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Figure 21. Kinetics of CD69 expression by fresh PBMC in response to 
TGN1412 stimulation in a HDC co-culture. Fresh CFSE-labeled PBMC 
were added to 2-day high-density precultured PBMC from the same donor 
and returned to high-density culture conditions for 0, 2, or 4 h before 
stimulation under standard conditions with 1 µg/mL TGN1412 for 2 h. 
Activation status was assessed by CD69 surface. Results are shown as 
percentage of CD69+ cells among the CD4+CD45RO+ population. Unpaired t 
test: *P<.05, **P<.005. Data are mean ± SD of triplicate samples. 
 
 Since monocytes are key players in the acquisition of TGN1412 reactivity in the 
RESTORE protocol, perhaps their functional status improves during the 2-day high-density 
culture of PBMC. Moreover, it is conceivable that such a maturation process again depends 
on interactions with the T-cells during HDC. To study this, monocytes were isolated from 
fresh PBMC and placed under high-density conditions, or were isolated from 2-day high-
density PBMC cultures. These two sets of monocytes were titrated and mixed with fresh 
CD4+ T cells from the same donor (Figure 22) in low cell density, and stimulated for 16 h. 
CD69 expression on fresh CD4+ T cells was induced very efficiently in the presence of 
monocytes isolated from high-density PBMC cultures, and to a lesser extent by high-density 
cultured monocytes. The OKT3 response did not vary with the source of monocytes present. 
These results suggest that monocytes functionally mature under high-density conditions in 
the presence of lymphocytes. This maturation renders them more efficient “accessory cells” 
and allows them to provide the necessary pre-activation signals to T cells in order for them to 
enter the sensitive state, and therefore respond to TGN1412. 
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Figure 22. Fresh CD4
+
 T cells acquire TGN1412 reactivity in the presence of monocytes 
derived from high-density PBMC cultures. Purified CD4+ T cells (5x105/0.5 mL) were cocultured in 
48-well plates at the ratios given with monocytes derived from high-density PBMC cultures, or with 
monocytes isolated from fresh PBMC and cultured for 2 days under high-density conditions. 
Stimulation with TGN1412 or OKT3 (1 µg/mL) for 16 h. Activation status of CD4+ cells was assessed 
by CD69 surface expression. Gray histograms represent unstimulated cells. Gated on CD4+ T cells. 
Data are mean  ± SD of triplicate samples. 
 
 
 
Figure 23. Monocyte phenotype in fresh and precultured PBMC. A. Monocyte phenotype from 
fresh and precultured PBMC, and B. phenotype of 2-day high-density precultured monocytes 
compared to monocytes within intact 2-day high density precultured PBMC. Gated on CD14+ T cells. 
Two different donors are shown in A and B. 
 
When cells mature they express or down regulate surface molecules that allow them 
to perform their functions. To identify a possible correlation between certain key surface 
markers and the monocyte function, surface stainings were performed for CD80, CD86, HLA-
ABC (MHC class I), HLA-DR,DQ (MHC class II) (Figure 23). Characterized monocytes were 
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from freshly isolated PBMC, high-density PBMC, or isolated monocytes kept 2 days under 
high-density conditions. Monocytes within high-density precultured PBMC had up-regulated 
MHC class I and CD86, compared to monocytes in freshly isolated cells (Figure 23A). MHC 
class II expression was lower on monocytes from HDC than on fresh monocytes (Figure 
23A). No major differences were observed for CD80. The up-regulation of surface markers 
depended on the presence of lymphocytes, since isolated monocytes cultured in high cell 
density for 2 days showed a similar phenotype to fresh monocytes (Figure 23B). These 
findings support the hypothesis of cell-cell interactions between different cell types during 
high-density PBMC culture. 
4.6. Human lymph node T cell response to TGN1412 
The toxic cytokine response elicited by TGN1412 during the clinical trial is most likely to have 
been by tissue resident CD4+ effector memory T cells (Figure 9). These cells no longer 
routinely enter the lymph nodes but remain mainly in non-lymphoid tissues (Bevan 2011; 
Sallusto, Geginat, and Lanzavecchia 2004).  
In rodent models it has been shown that tissue-resident memory T cells, as well as 
lymph node cells present a state of heightened antigen reactivity (Kassiotis et al. 2002; 
Stefanova, Dorfman, and Germain 2002). This pre-activation status of mouse lymph node 
cells can be lost both by experimental and physiological interruption of T-cell contact with 
self-peptide MHC ligands, leading to a rapid decline in signalling and response sensitivity to 
foreign antigens (Stefanova, Dorfman, and Germain 2002).  
To study the responsiveness of human tissue cells ex vivo, lymph node samples 
obtained from the pancreas of non-diabetic brain-dead multi-organ donors received at the 
Islet Isolation Facility of the San Raffaele Hospital, Milan, Italy, were stimulated with 1 µg/mL 
TGN1412 (Dr. Manuela Battaglia). In Figure 24 single cell suspensions were either kept on 
ice or at 37°C for 1 h in order to interrupt cell-cell contacts. There was a small but significant 
proliferative response to TGN1412, which was diminished to approximately half after being 
kept in suspension at 37°C. This result supports the concept that tissue-resident T cells, 
particularly LN cells, present a pre-activation state, which allows them to proliferate after 
TGN1412 stimulation. Importantly, the sensitive state can be lost by suspension culture, 
namely interruption of cellular interactions. 
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Figure 24. Human lymph node cells lose TGN1412 reactivity by 
suspension culture. Human lymph node (LN) cells were kept on ice 
or at 37°C (5% CO2) for 1 h in suspension (1x106 cell/mL), and the 
proliferative response to TGN1412 (1 µg/mL) was assessed. One of 
two individual experiments with similar results is shown. Two-way 
ANOVA: *P<.05. Data are mean ± SD of triplicate samples. Data are 
mean ± SD of triplicate samples. Experiment performed by Dr. 
Manuela Battaglia. 
 
 Memory T cells from circulating PBMC are the cell subset that responds to TGN1412 
stimulation in vitro after 2-day high-density preculture (Figure 8 and Figure 10). To identify 
the proliferating cell subset in human LN samples (obtained from the para-iliac region of renal 
transplant recipients at the Academic Medical Center, Amsterdam, Netherlands; Ineke ten 
Berge) cells were stained after TGN1412 stimulation with surface markers and the nuclear 
proliferation marker Ki67 (Figure 25). In accordance to the high-density precultured PBMC 
results, the main subset proliferating to TGN1412 stimulation were the CD4+CD45RO+ T 
cells. Again, this sensitive state can be lost by keeping LN cells in suspension, as seen by 
the reduction of responding cells to 39% after 2h, and 27% after 4h. Of note, keeping LN 
cells at high-cell density did not improve their reactivity (not shown). Fresh PBMC obtained 
from the same donor failed to respond to TGN1412 stimulation (Figure 25), in keeping with 
results shown previously (Figure 4). Taken together, these results support the notion that 
CD4 memory T cells depend on cell interactions given within tissues to maintain 
responsiveness to TGN1412. 
4.1. Pharmacologic inhibition of the precultured-T-cells response  
The RESTORE protocol represents a robust methodology that allows asking questions about 
the response to soluble TGN1412. Corticosteroid treatment is known to control the cytokine-
release-syndrome (CRS) generated by certain drugs, such as OKT3 (Goldman et al. 1989). 
Perhaps the CRS generated by TGN1412 could also be controlled that way. The cytokine 
release elicited both by TGN1412 and OKT3 on HDC PBMC was suppressed by 
Dexamethasone (Dex) with comparable efficiency (Figure 26). Methylprednisolone showed 
similar results (not shown). 
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Figure 25. Human LN cells are reactive to TGN1412 in contrast to PBMC, a 
state which is lost by suspension culture. Fresh LN cells were placed in 
suspension in low cell density (1x106 cell/mL), and either stimulated immediately with 
1 µg/mL TGN1412 or kept in suspension culture at 37°C, 5% CO2, for 2 or 4 h (top 
panel). A PBMC sample from the same donor was analyzed in parallel (bottom 
panel). Cell proliferation was determined after 4 days of stimulation by Ki67 staining. 
Gated on CD4+ cells. One of two individual experiments with similar results is shown. 
 
 
 
Figure 26. Corticosteroid suppression of TGN1412-induced cytokine release from 
precultured PBMC is of comparable efficacy as found with OKT3. HDC PBMC were 
stimulated with 1 µg/mL TGN1412 or OKT3, dexamethasone (Dex) was added at the final 
concentrations shown. Cytokine release was measured in cell culture supernatants by CBA. Data 
are mean ± SD of triplicate samples. 
  
 The fact that preculturing PBMC at high density renders T cells reactive to TGN1412 
suggests that the in vitro response to other substances involving the TCR could also become 
more sensitive. The OKT3 response is of equal magnitude for both fresh and precultured 
PBMC (Figure 3, Figure 4). The likely explanation for this is that because this high-affinity 
ligand addresses the TCR complex directly, the need for a pre-primed TCR machinery is 
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overcome. Nevertheless, it has been shown in mice that “tonic” TCR signals improve 
signaling intensity to cognate TCR ligands (Stefanova, Dorfman, and Germain 2002). 
Therefore, for example, signal transduction in fresh PBMC might be less sensitive to 
pharmacological inhibition than in HDC PBMC. To test this, OKT3 was used in a sub-optimal 
concentration (0.01 µg/mL), and as an inhibitor titrated amounts of the Lck inhibitor PP1, 
which blocks at the early steps of the TCR signal transduction cascade. High-density 
precultured PBMC were in fact less sensitive to PP1 inhibition than fresh PBMC (Figure 27).  
 
 
Figure 27. OKT3-stimulated HDC PBMC are less sensitive 
to PP1 inhibition than fresh PBMC. Proliferation of fresh and 
precultured PBMC stimulated with a suboptimal concentration 
of OKT3 (0.01 µg/mL) in the presence of titrated amounts of 
PP1. Data are mean ± SD of triplicate samples. 
 
An immunosuppressive drug widely used in organ transplantation to prevent rejection 
is the fungus metabolite cyclosporine A (CsA) (Borel et al. 1994). It is a cyclic nonribosomal 
peptide of 11 aminoacids that acts exclusively on T cells (Kaminski 2008). It binds to 
cyclophilin A forming a complex which inhibits TCR-induced calcineurin activity, therefore 
preventing the dephosphorylation of NFAT and transcription of cytokines such as IL-2 
(Schreiber and Crabtree 1992; Koenen et al. 2003). It therefore acts on a signaling molecule 
downstream of the TCR. This undecapeptide was tested for its ability to inhibit OKT3-induced 
T cell proliferation of fresh and precultured cells (Figure 28). Both responses were 
comparable, although a small but statistically significant difference was detected for a higher 
CsA concentration (125 ng/mL). 
Taken together, these results suggest that the use of fresh PBMC for in vitro testing 
of T-cell directed immunosuppressive substances might, in some cases, be misleading, 
because circulating T cells are in a non-primed state making them functionally disabled. 
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Figure 28. Cyclosporine A inhibition of the fresh and 
precultured PBMC response to OKT3. Proliferation of fresh 
and precultured PBMC stimulated with a suboptimal 
concentration of OKT3 (0.01 µg/mL) in the presence of titrated 
amounts of CsA was measured. Results shown as percentage 
of maximum OKT3 response. Paired t test for 125 ng/mL 
(*P<.05) Data are mean ± SD of triplicate samples. 
 
4.2. Response to T-cell mitogens 
Mitogens are substances that induce a cascade of biochemical events leading to mitosis 
(Lichtman, Segel, and Lichtman 1983). Widely used mitogens are lectins, which are proteins 
that specifically bind to membrane glycoproteins of cells. They act as mitogens by 
crosslinking cell surface receptors (Sharon and Lis 1972; Andersson, Sjöberg, and Möller 
1972). Concanavalin A (ConA) is a plant lectin from jack bean capable of binding non-
covalently to carbohydrate groups (mannose) located on the surface of T and B lymphocytes, 
although it selectively activates T cells by promoting an increase in the rate of calcium entry 
into the cell, resulting in DNA synthesis and cellular proliferation (McCole et al. 1998). 
Phytohemagglutinin (PHA) is a lectin found in plants, especially legumes, and it induces T-
cell proliferation and activation in the same manner as ConA does (Lichtman, Segel, and 
Lichtman 1983).  
Cell proliferation induced by PHA or ConA was greater after the cells were 
precultured in high density (Figure 29). Even though the results varied greatly (see SD), the 
difference between fresh and precultured PBMC proliferation was statistically significant. 
Together, these results suggest that the RESTORE protocol improves the mitogenic T-cell 
response to lectins. 
The CD2 molecule is a surface glycoprotein expressed on virtually all T cells, 
thymocytes and NK cells (Wang et al. 1999). It binds to LFA-3 (CD58) expressed on APC, 
promoting intercellular adhesion. This adhesion occurs at the initial stages of cell contacts 
between T cells and APC before T cell activation, when T cells are roaming the lymph nodes 
looking at the surface of APCs for cognate peptide:MHC complexes (Wang et al. 1999). LFA-
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3 together with anti-CD2 mAbs have a co-stimulatory function in activation of T cells (Hünig 
et al. 1987). By the use of mAbs that bind the CD2 molecule, it has been found that 
combinations of mAbs directed to appropriate epitopes of the molecule causes T-cell 
activation (Moretta et al. 1989; Tiefenthaler and Hunig 1989; Meuer et al. 1984). Since CD2 
stimulation depends on the TCR it was therefore hypothesized that precultured T cells might 
be more sensitive to !CD2 mAb stimulation. To elucidate this question, a stimulation of fresh 
and precultured PBMC was performed with an !CD2 antibody combination (M1, M2 and 
3PT). Figure 30 shows that cells that have been made reactive by the RESTORE protocol 
are more sensitive to !CD2 antibody stimulation than circulating cells (fresh), shown by 
increased TNF release. 
 
 
Figure 29. Mitogenic capacity of PHA and ConA on fresh and precultured PBMC. 
Difference between fresh and precultured curves is statistically significant for both PHA and 
ConA as determined by a Wilcoxon signed rank test (P<.05). Data are mean ± SD of 5 individual 
donors for PHA and 4 for ConA. 
 
 
 
Figure 30. TNF release upon !CD2 mAbs stimulation of 
fresh and precultured PBMC. mAbs M1, M2 (1 µg/mL) and 
3PT (0.33 µg/mL). Data represents TNF concentration on 
pooled triplicates of cell culture stimulation supernatants. 
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4.3. Response of precultured PBMC to bacterial antigens 
Stimulation of circulating PBMC is widely used to routinely test for recall responses to 
antigens and to identify antigen-specific memory T cells. However, mouse TCR-transgenic 
CD4 T cells isolated from lymphoid tissues lose sensitivity to their cognate antigen when kept 
in suspension, resembling what happens when cells go into the circulation (Stefanova, 
Dorfman, and Germain 2002). By resetting circulating PBMC to tissue-like conditions with the 
RESTORE protocol the in vitro response to recall antigens could presumably be improved. 
 Tetanus/diphtheria toxoid (Td) is a common vaccine that is recommended in most 
countries, such as the United States and Germany, to be applied to children under a year of 
age (ACIP 2012; Kroger et al. 2011; STIKO 2011). This vaccine generates memory cells that 
can give a protective recall response when exposed to the infection or upon in vitro 
stimulation. Proliferative Td recall response was greatly enhanced by high-density preculture 
of PBMC (Figure 31). 
Pathogenic microbes such as viruses, mycoplasma and bacteria, can produce 
another kind of antigens or exotoxins called superantigens, which cause excessive and 
aberrant non-specific T cell activation and can activate up to 20% of the T-cell compartment 
in vivo, provoking a massive cytokine release, and causing a broad range of health 
problems. The best characterized are the staphylococcal enterotoxins (SEA, SEB, etc.) and 
the streptococcal pyrogenic exotoxins that trigger the staphylococcal and streptococcal toxic 
shock syndromes (Llewelyn and Cohen 2002). When SEB was tested for its mitogenic 
activity on fresh and precultured PBMC, the latter showed to have increased sensitivity to the 
superantigen stimulation (Figure 32). 
 
 
Figure 31. Proliferative response to Td of fresh and precultured PBMC. A. Compilation of 
tetanus/diphtheria toxoid (Td) recall responses of 6 random healthy donors. B. Dose response to Td of 
the stronger responder shown in A (blue line). The difference between fresh and precultured paired 
values was statistically significant as determined by a Wilcoxon signed rank test (P<.05). Data 
represents mean ± SD of triplicate samples. 
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Figure 32. Proliferative response to SEB of fresh 
and precultured PBMC. Data represents mean ± 
SD of triplicate samples. 
 
4.4. Role of the Fc portion of CD28 superagonists on T- cell stimulation 
TGN1412 is an IgG4 antibody, i.e. of the isotype for which FcR have lower affinity than for 
other isotypes, such as IgG1 (Presta and Namenuk 2005). FcR ligation improves the 
activation capacity of some antibodies like OKT3. Despite this fact, TGN1412 is very active 
both in vivo and in high-density precultured PBMC. Based on the experience with OKT3, the 
hypothesis arose that TGN1112, an IgG1 version of TGN1412, should be even more active 
than the IgG4 counterpart. However, when mitogenic activity was tested on precultured 
PBMC, TGN1412 showed to be much more active that TGN1112 (Figure 33). 
 
 
Figure 33. Mitogenic activity of TGN1412 and 
TGN1112 on HDC PBMC. Proliferation of 
precultured PBMC stimulated with titrated amounts 
of the superagonists (SA) TGN1112 and TGN1412. 
Data are mean ± SD of triplicate samples. 
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The difference in the antibody shape between TGN1112 and TGN1412 (IgG1 and 
IgG4) (Aalberse and Schuurman 2002) might cause steric interferences which might 
influence their binding and therefore their activation capacity. Ligation of the Fc portion by 
FcR on other cells might also have an effect on the stimulatory activity. Therefore Fab and 
Fab2 fragments from TGN1112 and TGN1412 were generated. Surprisingly, Fab2 fragments 
of both TGN1112 and TGN1412 had a mitogenic effect on HDC PBMC (Figure 34). The 
monomeric Fab fragments did not induce proliferation, which is most likely due to the fact 
that the CD28 superagonists need to crosslink two CD28 molecules in order to activate T 
cells. 
 
 
Figure 34. Mitogenic activity of intact, Fab and Fab2 fragments from TGN1112 and TGN1412 
antibodies on precultured PBMC. Proliferation of precultured PBMC stimulated with titrated amounts 
of TGN1112, TGN1412 and their Fab and Fab2 fragments. Data are mean ± SD of triplicate samples. 
 
 A finer titration was performed for intact and Fab2 TGN1112 and TGN1412 on 
precultured PBMC (Figure 35). Donor dependent variability was observed, but the tendency 
remained. Both Fab2 fragments presented a concentration-dependent mitogenic activity, 
while intact TGN1112 did not induce cell proliferation. Of note, the stimulatory effect of intact 
TGN1412 reached saturation at the highest concentrations, while the Fab2 presented a bell-
shaped response. This type of response is explained by a phenomenon termed the 
Heidelberger-Kendall curve (Heidelberger and Kendall 1929), which will be discussed later. 
Fab2 fragments also showed to have the capacity to induce cytokine release on 
precultured PBMC, as shown in Figure 36 by TNF release. In accordance to the proliferation 
data, cytokine release response was stronger with TGN1112 Fab2 than with TGN1412 Fab2. 
Intact TGN1112 antibody does not induce TNF release. This goes to show that TGN1112 is 
more active without the Fc portion, i.e. as a Fab2 fragment. 
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Figure 35. Mitogenic activity of intact and Fab2 fragments from TGN1112 and TGN1412 
antibodies on precultured PBMC. Proliferation of precultured PBMC stimulated with a fine titration of 
TGN1112, TGN1412 and their Fab and Fab2 fragments. Data are mean ± SD of triplicate samples. 
 
 
 
Figure 36. TNF release by precultured PBMC in response to intact and 
Fab2 TGN1112 and TGN1412. TNF release measured by CBA in cell 
culture supernatants after 24h stimulation. Data are mean ± SD of three 
different blood donors for intact Ab, and of two donors for Fab2. 
 
It is intriguing that TGN1112 does not have stimulatory capacity as its IgG4 
counterpart (TGN1412), but it does when the Fc portion is removed. Binding affinity or 
binding dynamics of the antibodies could influence their stimulatory capacity. Therefore the 
binding kinetics of intact, Fab and Fab2 fragments of TGN1112 and TGN1412 were 
compared. First, binding kinetics of TGN1412-FITC was studied at two different 
temperatures, 4°C and 37°C for fresh and precultured PBMC. In Figure 37 binding of 
TGN1412-FITC at a suboptimal concentration (0.3 µg/mL) on fresh and precultured PBMC is 
shown. As expected, TGN1412 binds faster at 37°C than at 4°C, since Ab-Ag interactions 
are increased at physiological temperature, i.e. by faster movement of the antibodies and of 
the cells. Based on these results, all subsequent binding assays were performed at 37°C. It 
can also be seen that binding of TGN1412 reaches saturation after 4 hours of incubation at 
37°C. There is no difference in binding kinetics between fresh and precultured cells. 
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Figure 37. TGN1412 binding kinetics on fresh and precultured PBMC at 
4°C and 37°C. Fresh and precultured PBMC were stained with 0.3 µg/mL 
TGN1412-FITC for the timepoints indicated. 
 
To study the binding kinetics in more detail, CD4+ T cells were isolated from freshly 
obtained PBMC. The experiment was performed in RPMI + 10% FCS. PBMC were placed in 
the incubator at 37°C, 5% CO2, in the presence or absence of the intact antibodies, Fab or 
Fab2 fragments, of TGN1112 or TGN1412 for different time points, harvested, washed, and 
stained with a fluorochrome-conjugated monoclonal antibody directed against the human 
kappa light chain (Figure 40). This secondary antibody allows proper comparison of the 
amount of intact antibodies as well as single Fab and Fab2 fragments bound to the cell 
surface. 
It is important to keep in mind that CD28 superagonists bind exclusively to the 
laterally exposed C))D loop of the extracellular immunoglobulin-like domains of CD28, in 
contrast to conventional anti-CD28 antibodies, which recognize an epitope close to the 
binding site for binding to the natural ligands CD80/CD86 (Luhder et al. 2003). Monomeric 
Fab fragments of TGN1412 and TGN1112 (Figure 38 and Figure 40) achieved binding 
equilibrium already after 10 minutes of incubation, and saturation was reached at 1 µg/mL 
(Figure 38A). The amount of CD28 surface expression remained constant in time. A 
schematic representation of the possible binding behavior of the Fab fragments is shown in 
Figure 38B, under saturating concentrations and when binding equilibrium is reached.  
Antibodies have two antigen binding sites, so they can potentially bind bivalently to 
antigens. The lateral binding mode of CD28 superagonists suggests crosslinking of CD28 
dimers on the cell surface (Evans et al. 2005). Figure 39 supports the notion that TGN1412 
binds bivalently, but this process takes time. During the first 2h of incubation antibodies bind 
with one arm to CD28, when in excess (Figure 39B). Binding equilibrium is reached after 4 
hours of incubation and it is maintained for at least 20 hours (Figure 39C). Of note, the MFI 
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after 10 minutes is double the value than after 4h with saturating antibody amounts (4 
µg/mL), which supports the hypothesis of a transition from monovalent to bivalent binding of 
CD28SA. Binding stability is much higher with bivalent binding, since the interaction of the 
antigen binding site with their ligand is not a static phenomenon, it opens and closes, so the 
chance that at least one arm of the antibody is bound is much higher. This translates in 
higher avidity (in orders of magnitude) of the antibody. 
 
 
Figure 38. TGN1412 Fab fragment binding kinetics on isolated CD4
+
 T cells. A. MFI 
of TGN1412 Fab on isolated CD4+ T cells from fresh PBMC. B. Schematic representation 
of TGN1412 Fab fragment binding to CD28 on T cells in saturation when binding 
equilibrium is reached. 
 
 
Figure 39. Intact TGN1412 antibody binding kinetics on isolated CD4
+
 T cells. A. 
MFI of TGN1412 Fab on isolated CD4+ T cells from fresh PBMC. B. Schematic 
representation of TGN1412 binding above saturation to CD28 on T cells after short 
incubation, and C. when binding equilibrium is reached. 
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Importantly, the binding kinetics of TGN1412, TGN1112 and their Fab2 fragments is 
nearly identical (Figure 40), so the difference in the stimulatory capacity of these two 
antibodies must have a different explanation. 
 
 
Figure 40. TGN1112 and TGN1412 intact antibodies, Fab and Fab2 fragments binding kinetics 
on isolated CD4
+
 T cells. MFI of TGN1112, TGN1412 and their Fab and Fab2 fragments on isolated 
CD4+ T cells from fresh PBMC over time. 
 
There does not seem to be any steric interference with binding due to the antibody 
shape or by the Fc portion. Nevertheless, intact TGN1112 does not activate T cells, but the 
Fab2 fragment does, so the Fc portion seems to play a role. To determine if the binding 
kinetics differs in any way in the presence of other Fc expressing cells the experiment shown 
in Figure 40 was repeated but with freshly isolated intact PBMC (Figure 41), with surprising 
results. First of all, Fab and Fab2 fragments bind in the same way to CD4+ T cells in intact 
PBMC as to isolated CD4+ T cells. In contrast, T cells incubated with intact antibodies seem 
to lose surface expression of CD28, especially in the case of TGN1112. Binding equilibrium 
is reached after around 4h of incubation (Figure 39C), but drops dramatically after 18h. 
A plausible explanation for this phenomenon is that the antibody is being ripped-off 
from the T-cell surface by other cells through Fc-FcR interactions, especially TGN1112 being 
an IgG1, in which the Fc part is more available than IgG4, and has a higher binding affinity. It 
has been reported that CTLA-4 can capture its ligands from opposing cells by a process 
called trans-endocytosis (Qureshi et al. 2011); such a process could also help explain the 
CD28 + TGN1112 disappearance from the cell surface. 
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Since Fc receptor affinity is lower for TGN1412, CD28 might be being “less” ripped off 
from the surface, or perhaps this is due to the fact that the Fc portion of TGN1112 is more 
available than TGN1412, hence difficult to reach by FcR bearing cells (Aalberse and 
Schuurman 2002). 
 
 
Figure 41. Binding kinetics of TGN1112 and TGN1412 intact antibodies, Fab and Fab2 
fragments on intact PBMC. MFI of TGN1112, TGN1412 and their Fab and Fab2 fragments on freshly 
isolated PBMC over time. 
 
 
Figure 42. TGN1112 binding kinetics on CD4
+
 T cells and monocytes. MFI of TGN1112-FITC 
binding to the CD4+ T cell surface and increase of FITC signal detected on monocytes. Staining 
performed on freshly isolated intact PBMC. 
 
Fluorescently labeled antibodies can be traced by FACS analysis. In order to 
determine whether TGN1112 is indeed ripped-off from the cell surface of T cells, TGN1112-
FITC was used to stain the cells. If the FITC signal were detected on other cells, this would 
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support the theory of trans-endocytosis. After 18h there was no antibody bound to the cell 
surface of CD4+ T cells anymore (no CD28 expression) (Figure 42). When gating on 
monocytes, an increase in FITC signal was detected, proportional to the antibody 
concentration and to the disappearance from the T cell surface (Figure 42). Since monocytes 
do not express CD28, this finding leads to the conjecture that monocytes rip-off CD28-
TGN1112 complexes from the surface of T cell via Fc-FcR interactions. 
  
 
Figure 43. TGN1112 has low mitogenic activity on precultured PBMC but it induces 
IFN-#  production and CD69 expression in short-term sensitive assays. A. 
Proliferation of precultured PBMC stimulated with TGN1112 intact and Fab2, measured 
from day 2-3 by [3H]Thymidine incorporation. B. IFN-# producing cells measured by 
ELISPOT after 16h stimulation of precultured PBMC. C. CD69 expression by CD4+ T cells 
in precultured PBMC induced by 16h stimulation with 1 µg/mL intact TGN1412 or 
TGN1112 mAbs. Lymphocyte gate. A, B and C are results from the same donor. Data 
represents mean ± SD of triplicate samples. 
 
This phenomenon might explain why TGN1112 has no mitogenic activity, since this 
“regulatory” mechanism occurs early enough to prevent cells to get the activation signal for a 
sufficient time to proliferate. Proliferation is measured from day 2 to 3 of the stimulation, 
which might be a too late read-out of the effect of TGN1112. To have a more sensitive short-
term assay, an IFN-# ELISPOT was performed. Cytokine-producing cells could indeed be 
detected after 16h stimulation with soluble TGN1112 though to a much lower extent than with 
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the Fab2 fragments (Figure 43B), which shows that the intact antibody has an initial 
stimulatory effect that might be being blocked or stopped by ripping the antibody off from the 
cell surface, as seen in the low counts obtained in the proliferation assay (Figure 43A). 
TGN1112 Fab2 induced a very strong cytokine release (Figure 43B), supporting the 
hypothesis of the involvement of the TGN1112 Fc part on the regulation of the response. 
CD69 expression, an early T-cell activation marker, is also a good read-out for short-term 
responses. TGN1112 induced CD69 expression on 46% CD4+ T cells, while TGN1412 
induced it on 79% (Figure 43C). Nevertheless, it is clear that TGN1112 has a short-term 
stimulatory effect on T cells. 
 The binding experiments were done using RPMI + 10% FCS as medium. Human AB 
serum contains many more immunoglobulins than FCS, approximately 10 mg/mL (Cassidy, 
Nordby, and Dodge 1974). These Igs could compete with the antibodies added for FcR 
binding, so TGN1112 might not be ripped off by FcR-positive cells in a physiological 
situation.  
 
 
Figure 44. Binding kinetics of TGN1112 and TGN1412 intact antibodies on PBMC 
or isolated CD4
+
 T cells in the presence of human serum. MFI of TGN1112 and 
TGN1412 on freshly isolated PBMC or isolated CD4+ T cells over time, using AB 
medium. Gated on CD4+ cells. 
 
 This hypothesis was tested by performing a similar experiment as shown in Figure 40 
and Figure 41, but in medium containing 10% human AB serum (AB medium). TGN1412 was 
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only ripped off to a small degree from the cell surface in the presence of other cells, as it has 
been shown before in FCS-supplemented medium, where it was more pronounced (Figure 
41). The IgG1 version of the anti-CD28 SA, TGN1112, which was completely ripped-off in 
medium with FCS (Figure 41), was also removed from the T cell surface in intact PBMC in 
the presence of AB serum but to a lesser extent, while on isolated CD4+ T cells it was not, 
instead it reached binding equilibrium as shown in previous experiments. These observations 
suggest that the limited stimulatory activity of TGN1112 might be indeed due to the fact that 
the antibody is ripped-off from the T cell surface before it an induce proliferation. This might 
also occur physiologically, since the phenomenon was observed in the presence of human 
serum, leaving TGN1412 as the most effective anti-CD28SA to induce T-cell activation and 
proliferation. 
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5. Discussion 
The unexpected and tragic outcome of the CD28 superagonist TGN1412 first-in-man clinical 
trial in 2006 was not predicted by any of the preclinical studies done with circulating human 
PBMC (Duff 2006) or animal models including rats (Lin and Hunig 2003), mice (Dennehy et 
al. 2006), and rhesus (TeGenero 2005) and cynomolgus monkeys (Duff 2006). In contrast, 
the rat superagonist JJ316 showed to preferentially activate Treg cells (Lin and Hunig 2003), 
thus favoring the clinical improvement in several autoimmune disease models (Schmidt et al. 
2003; Beyersdorf, Hanke, et al. 2005). The need for new methods that would allow to predict 
this cytokine release syndrome immediately arose. 
 As introduced previously several approaches have been made to find an explanation 
on the failure of circulating PBMC to predict the TGN1412-induced cytokine storm and to find 
in vitro assays that mimic the response observed in vivo (Stebbings et al. 2007; Findlay et al. 
2010). These include immobilization of TGN1412 by air-drying or wet-coating the plates, or 
captured by immobilized anti-Fc antibodies. Eastwood et al. (2010) point out that 
immobilizing a mAb to a plastic surface is a highly artificial system that is unlikely to simulate 
a physiological situation. Plastic immobilization does allow predicting in vitro if a drug would 
activate cells, but titrations are not possible. 
 Another finding is that TGN1412 can activate T cells in the presence of an endothelial 
layer (primary umbilical vein endothelial cells or HUVECs), although the results obtained by 
Stebbings et al. (2007) show a very poor TNF response in the presence of a HUVEC layer 
after 16-24h TGN1412 stimulation, similar to the one obtained by Findlay et al. (2011), who 
also report that the profile of released cytokines after 24h TGN1412 stimulation in the 
presence of endothelial cells did not mirror that in the clinical trial volunteers or the plastic-
immobilized TGN1412. Recently, Weissmüller et al. (2012) agreed that the TGN1412 
response depends on the interaction with endothelial cells. They showed that this does not 
depend on interactions between Fc-FcR, finding that supports the observation of Findlay et 
al. (2011) who show that TGN1412 does not bind to HUVECs; they claim it depends instead 
on the interaction of the ICOS (CD278) expressed on activated T cells with its ligand (LICOS 
or CD275). Human endothelial cells constitutively express low levels of LICOS, which is 
strongly upregulated during an immune response, namely in the presence of pro-
inflammatory cytokines such as TNF-!, IFN-# or IL-1" (Moore 1999). Weissmüller et al. 
(2012) showed T cell cytokine release upon TGN1412 stimulation in the presence of 
cytokine-preactivated HUVECs (TNF-! + IFN-# for 3 days), a condition that would account 
for an active immune response, which was not the case in the healthy volunteers previous to 
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TGN1412 infusion. Therefore although this ICOS-LICOS interaction might occur in tissues 
boosting an existing immune response, it cannot explain the initial T-cell activation by soluble 
TGN1412 observed in vivo. 
 In contrast, we found that by simple preculture of circulating human PBMC under 
high-cell density conditions for two days T cells became TGN1412 reactive. The response 
obtained, both mitogenicity and cytokine release, was of comparable magnitude to that 
obtained with the anti-CD3 mAb OKT3, response that is well studied and characterized. Both 
of these antibodies induced a similar in vivo response in humans, namely a cytokine release 
syndrome that can be controlled by corticosteroids (Abramowicz et al. 1989; Chatenoud et al. 
1990; Duff 2006). Importantly, the cytokine release profile obtained with the 2-day high-
density preculture of PBMC corresponds to the one measured during the TGN1412 first-in-
man clinical trial, reported by Suntharalingam et al. (2006). The hypothesis behind these 
observations is that cells are acquiring tissue like properties by being first exposed to a 10-
fold higher cell density than what is used in standard immunological assays. Cells are highly 
packed together, having therefore many more interactions as they do within tissues. The 
acquisition of TGN1412 reactivity depends on these cell-cell contacts, which could be due to 
both adhesion-induced T cell priming, which occurs upon binding to artificial substrates such 
as immobilized ligands as well as upon interaction with dendritic cells (Randriamampita et al. 
2003), and due to "tonic signals" obtained by MHC scanning by the TCR (Stefanova, 
Dorfman, and Germain 2002). Reactivity of lymph node T cells to TGN1412 stimulation 
supports this idea. Importantly, performing TGN1412 stimulation of high-density precultured 
PBMC in the presence of a HUVEC cell monolayer did not improve the response (not 
shown). 
 A possible explanation for this re-acquisition of T-cell reactivity to TGN1412 could be 
the enrichment or depletion of a particular cell subset after the preculture, but this was not 
the case. HDC cells also did not lose a hypothetical suppressive capacity, because when 
mixed with fresh cells there was no inhibition of the response. This means that T cells are 
gaining function or reactivity by the RESTORE protocol. 
  A previous study showed that release of proinflammatory cytokines in vitro by 
immobilized TGN1412 stimulation of human PBMC was by CD4 effector memory cells 
(Eastwood et al. 2010). This finding was confirmed with the RESTORE protocol using soluble 
TGN1412, where the CD4+CD45RO+CCR7- population released IFN-" and TNF and 
proliferated upon stimulation. Thus the "cytokine storm" elicited in the human volunteers 
upon TGN1412 infusion might have been released by the CD4 effector memory cell 
compartment, which is localized mainly in peripheral tissues such as the gut or the lungs 
 71 
 
(Sallusto et al. 1999). Cytokines likely released by tissue resident T cells diffused to the 
circulation, causing a systemic reaction. Of note, 90% of the body's lymphocytes reside in the 
lungs and gastrointestinal mucosa, while the blood contains only around 1% (Cerf-
Bensussan and Guy-Grand 1991; Smit-McBride et al. 1998). It has also been determined 
that naive and central memory CD4+ T-cell subsets have limited potential for cytokine 
expression, in contrast to the effector memory subset which presents a considerable 
capability for cytokine production. Importantly, IFN-" expression has been shown to be 
largely limited to the CD4+ effector memory T-cells (Sallusto et al. 1999; Amyes, McMichael, 
and Callan 2005). Of importance, we showed that the cytokine release induced by TGN1412 
could be controlled by corticosteroids (namely methylprednisolone and dexamethasone). The 
use of high doses of these anti-inflammatory agents proved, in animal models, not to 
interfere with the activation of Treg cells, suggesting that the desired effect of Treg activation 
could be obtained in humans by co-administration of corticosteroids (Gogishvili et al. 2008). 
 Phosphorylation of tyrosine residues on intracellular proteins or ITAMs 
(immunoreceptor tyrosine-based activation motifs) on the cytoplasmic tails of membrane 
receptors after appropriate ligand binding events leads to the initiation of intracellular 
signaling cascades and cell activation (Cambier 1995). Previous studies in a mouse model 
showed that lymph node cells present a constitutively phosphorylated CD3 molecule (p21 of 
the CD3& chain), while circulating T cells do not (Stefanova, Dorfman, and Germain 2002). 
This is probably due to tonic signals through MHC recognition by the TCR in the densely 
packed tissue environment. It has been shown that CD28SA mitogenic activity depends on 
tonic signals (Hünig and Dennehy 2005). The RESTORE protocol allowed the recovery of 
protein phosphorylation associated with the TCR (probably p21 on the CD3& chain) seen in 
human lymph node cells, and the formation of cap-like structures was observed as well, 
where pTyr and CD3 colocalized, supporting the notion of the generation of pre-activated 
TCR complexes. Activated Lck (Src-family kinase) phosphorylates the CD3& chain, 
promoting the recruitment of the Syk/ZAP-70 family of kinases to the TCR complex (van Oers 
1999). MHC scanning reportedly leads to phosphorylation of ZAP70 (Stefanova, Dorfman, 
and Germain 2002), which phosphorylates SLP-76, promoting the recruitment of Vav (a 
guanine nucleotide exchange factor), adaptor proteins, and an inducible T cell kinase (Itk) (Qi 
and August 2007). It has been shown that CD28SA are able to amplify tonic signals at the 
level of the SLP-76/Vav/Itk signalosome, which becomes phosphorylated after CD28 
costimulation, and it seems to cooperate in the activation of downstream molecules such as 
PLC-# (Figure 45) (Hünig and Dennehy 2005). Furthermore, Goghisvili et al. (2008) 
demonstrated that CD28 ligation can mediate Lck- and Vav1-dependent proliferative signals 
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independently of PI3K. The fact that inclusion of PP1, which inhibits Lck, into the high-density 
2-day preculture actually impeded the sensitization of T cells to TGN1412 supports the 
findings that lead to the hypothesis that tonic signals received via TCR scanning induce the 
formation of a pre-activated TCR machinery, rendering T cells more sensitive to stimulation. 
 
 
Figure 45. CD28SA T-cell activation depends on 
TCR tonic signals. Schematic representation of 
CD28SA intracellular signaling (Hünig and Dennehy 
2005)*. 
 
 When MHC scanning was blocked with antibodies or Fab fragments against HLA 
class I and II, T cells failed to acquire full TGN1412 reactivity. The fact that both !HLA class I 
and II antibodies would block acquisition of TGN1412 reactivity could be confusing, because 
most of the cytokine producing cells are CD4+ T cells, which recognize HLA class II. 
However, most of the binding interface (75–80%) of the TCR involves contact between the 
gene–encoded components (complementarity-determining region 1 (CDR1) and region 2 
(CDR2)) and the conserved parts of the MHC helices. Ergo, the TCR V-gene repertoire is 
specific for MHC molecules regardless of the MHC class or allele (Wu et al. 2002; Matsui et 
al. 1991; Garcia et al. 2009). 
 As discussed, tonic signals occur in a densely packed cell environment, such as the 
one in lymph nodes, tissues or in the RESTORE protocol. Hochweller et al. (2010) 
demonstrated that in the mouse lymph nodes T cells obtain the preactivated state by 
scanning of DC, a cell type that is scarce in the blood. In the RESTORE system monocytes 
seem to play an important role, by helping overcome the lack of DC among PBMC. But why 
does the acquisition of reactivity takes 2 days, when recovery of reactivity in the mouse 
system on a DC/CD4+ T cell coculture takes only a few hours? (Hochweller et al. 2010). 
Monocytes seem to functionally mature after high-density preculture in the presence of 
accessory cells, as seen by the rapid increase of sensitivity of fresh CD4+ T cells to 
                                                
*
 Reprinted from Immunology Letters, 100/1, Thomas Hünig, Kevin Dennehy, CD28 superagonists: Mode of 
action and therapeutic potential, 21-28, 2005, with permission from Elsevier. 
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TGN1412 stimulation when cocultured with precultured monocytes, so both monocytes and 
CD4+ T cells need time to functionally mature so the latter can become TGN1412-reactive. A 
difference observed between fresh and precultured monocytes was the upregulation of MHC 
class I in the former, a molecule that is scanned by the TCR. 
 T cells present an all or nothing effect after preculture in response to TGN1412. For 
other T cell activating agents the effect of preculture is not absolute which could account for 
the reason that the impaired T cell responsiveness was not previously appreciated in 
humans. T cell response inhibition was less pronounced after the PBMC were precultured at 
high cell density for 2 days, namely T cells from precultured PBMC were less sensitive to 
PP1 blockade after OKT3 stimulation, and to a lesser extent, to CsA. T cell mitogens showed 
to be more potent on precultured T cells (PHA, ConA, !CD2 Abs), and HDC T cells also 
showed increased sensitivity to the bacterial superantigen SEB. Detection of recall 
responses to antigens is a very important diagnostic tool, and it is routinely performed in 
diagnostic laboratories to detect previous or latent infections or vaccination status. High-
density preculture of PBMC improved the recall response to tetanus/diphtheria toxoid.  
Taken together these results show that the RESTORE protocol might have important 
implications in preclinical assays on T-cell directed drugs, as well as a simple, cost-effective, 
and straightforward diagnostic tool. It has already been used to test the immunomodulatory 
activity of crude extracts derived from marine-sponge associated bacteria containing 
secondary metabolites (Tabares et al. 2011), as well as on CD8+ T cell-directed viral 
antigens (J. Fischer and T. Hünig, unpublished). In both studies the response was higher and 
more sensitive at low doses of the stimulants after PBMC were precultured at high cell 
density for 2 days, proving that the method is a more sensitive read-out for immunological 
stimulants. 
 This method allowed to reveal, for the first time, the in vitro cytokine release induced 
by soluble TGN1412. It was demonstrated by others that the antibody concentration used in 
the clinical trial, which was determined by in silico calculations (0.1 mg per kg body weight) 
(Duff 2006), achieved 45-80% receptor occupancy (Figure 46A) (Waibler et al. 2008), 
equivalent to 1 µg/mL in vitro, concentration which also showed to be in functional saturation 
as determined by the RESTORE protocol (Figure 4B, Figure 46B). The threshold for TNF 
induction by TGN1412 is at < 5% receptor occupancy (0.06 µg/mL, Figure 46). In the light of 
these observations it is clear that the amount of antibody infused in the healthy volunteers 
during the clinical trial was over-dosed. 
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Figure 46. Receptor occupancy and activation threshold of TGN1412. Median of the 
percentage of specific TGN1412 binding to CD3+ cells (open symbols). Each curve represents a 
different experiment. Black squares represent negative control (!CD20 Ab) (Waibler et al. 2008)†. 
B. TNF release after TGN1412 stimulation of PBMC, as seen in Figure 4B. The grey bar in both 
panels represents the theoretical concentration range achieved in the blood of the TGN1412 
clinical trial volunteers. Calculations done in A yielded 45-80% receptor occupancy of the antibody 
(Waibler et al. 2008). 
 
 The concentration of TGN1412 infused to the volunteers in the first-in-man trial was 
determined using the “no observed adverse effect level” (NOAEL) approach, based on 
results obtained in cynomolgus monkeys. This method determines the highest concentration 
of a substance at which there was no adverse reaction. The tolerated dose in primates was 
very high (50 mg/kg body weight). This value was then lowered by an adjustment factor and 
a safety margin, resulting in a dose 500 times lower (Duff 2006), meaning 0.1 mg/kg body 
weight was administered during the London Trial, which, as mentioned, was in functional 
saturation and very high level of CD28 occupancy (Waibler et al. 2008). 
It is now known that macaque CD4+ effector memory cells do not express CD28 on 
the cell surface, which is the subset that responds to TGN1412 stimulation (Eastwood et al. 
2010). This explains the failure of the CD28SA to induce cytokine release in the macaque 
model. NOAEL calculations were made based on these misleading observations. Following 
the very serious adverse reactions that occurred in the first-in-man clinical trial of TGN1412 
in March 2006, the European Medicines Agency (EMA) changed the rules for calculating the 
entry dose of biologicals in clinical trials (EMA 2007). An Expert Scientific Group on Phase I 
Clinical Trials was established to review and improve the safety of early clinical trials. In the 
report 22 recommendations were outlined that covered several aspects regarding safety of 
preclinical and early clinical development of biologicals. Among these, the “minimal 
                                                
†
 Reprinted from Journal of Allergy and Clinical Immunology,122/5, Zoe Waibler, Linda Y. Sender, Christel 
Kamp, Jan Müller-Berghaus, Bernd Liedert, Christian K. Schneider, Johannes Löwer, Ulrich Kalinke, Toward 
experimental assessment of receptor occupancy: TGN1412 revisited, 890-892, 2008, with permission from 
Elsevier.  
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anticipated biological effect level” (MABEL) approach is suggested for entry dose 
calculations. It takes into account many parameters that include: the novelty of the agent, its 
biological potency and its mechanism of action, the degree of species-specificity of the 
agent, the dose-response curves of biological effects in human and animal cells, dose-
response data from in vivo animal studies, pharmacokinetic and pharmacodynamic modeling 
and the calculation of target occupancy (Duff 2006). If the entry dose would have been 
calculated using the MABEL approach, the TGN1412 concentration would have been at least 
200-fold lower (Hünig 2012). In hindsight, the tragic outcome of the failed TGN1412 London 
trial may have contributed to increase safety standards for the future development of 
immunomodulatory drugs. 
 When the humanized version of the CD28SA was developed by TeGenero, IgG4 was 
the isotype of choice, due to its poor binding affinity to FcR, which translates in a lower 
likelihood of attracting cytotoxic effector mechanisms (Duff 2006), ergo antibody-dependent 
cell-mediated cytotoxicity or complement-dependent cytotoxicity (Hansel et al. 2010). 
Nevertheless there was an IgG1 version developed as well, TGN1112, isotype that binds 
FcR with high affinity and this ligation is known to improve the activation capacity of some 
antibodies (Presta and Namenuk 2005). In contrast to TGN1412 that had such a huge effect 
in humans, both in vivo and in vitro (RESTORE), TGN1112 did not show to have a mitogenic 
activity on T cells in vitro. A plausible explanation is that the differences in the antibody 
shape between IgG1 and IgG4 (Aalberse and Schuurman 2002)  of the human CD28SA 
might have an effect on the binding to CD28 and therefore on T cell activation. As depicted in 
Figure 47, IgG4 presents a flat shape resembling a boomerang, while IgG1 has the classical 
shape of an antibody shown in textbooks. TGN1112)s structure might cause steric 
interference so the antibody cannot crosslink two CD28 molecules on the cell surface, 
preventing T cell activation. 
In this context it is important to keep in mind that “conventional” costimulatory !CD28 
antibodies bind close to the CD80/CD86-binding site to CD28 (at the top of the molecule) in a 
monovalent fashion (Figure 1). In contrast, CD28SA bind laterally to the C))D loop allowing 
lattice formation by crosslinking CD28 homodimers (Luhder et al. 2003; Evans et al. 2005; 
Beyersdorf, Hanke, et al. 2005). 
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Figure 47. Model of the structure of IgG1 compared to IgG4. The structure of 
IgG1 is in accordance to the classical antibody structure, while IgG4 presents a 
compact structure (Aalberse and Schuurman 2002)‡. 
 
The type of proliferative response seen with Fab2 fragments presented a bell-shaped 
curve. This kind of behavior has been explained by Heidelberger and Kendall (1929), when 
they described quantitatively the formation of a precipitate when an antigen-antibody 
complex formed. When the amount of antigen added was increased, the degree of 
precipitate followed a bell-shaped curve as shown in Figure 48, where the formation of 
precipitate depends on the amount of antigen (ligand) and antibody. This type of behavior 
can be adapted to the context of this work. For the Fab2 fragments it is shown as the 
percentage of maximum proliferative response achieved (Figure 48), the ligand excess would 
be equivalent to lower concentrations of Fab2 (antibody) in the presence of T cells 
expressing CD28 (ligand). Under these conditions there are not enough Fab2 molecules to 
crosslink sufficient CD28 dimers on the surface of T cells to induce T-cell activation (Figure 
48A). When enough Fab2 is added the maximum response is achieved, due to maximum 
crosslinking (equivalence zone, Figure 48B), but when higher concentrations of antibody are 
added, the excess does not allow CD28-crosslinking anymore, hence a lower proliferative 
response was detected (Figure 48C). On the other hand, as expected, monomeric Fab 
fragments did not induce proliferation or cytokine release, since it is known that CD28SA 
need to crosslink CD28 dimers in order to activate T cells (Figure 1C) (Luhder et al. 2003; 
Evans et al. 2005; Beyersdorf, Hanke, et al. 2005). Intact TGN1412 response does not follow 
this behavior probably because of (although weak) interactions with the Fc part of the 
antibody with FcR expressed on other cells that might modulate the response to a certain 
degree by allowing secondary crosslinking. 
                                                
‡
 Reprinted from Immunology, 105/1, Rob C. Aalberse, Janine Schuurman, IgG4 breaking the rules, 9-19, 2002, 
with permission from John Wiley and Sons. 
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We considered the possibility that the shape or tertiary structure of TGN1112 as an 
IgG1 antibody does not allow crosslinking of CD28 molecules. The fact that Fab2 fragments 
of both TGN1112 and TGN1412 did activate T cells from high-density precultured PBMC 
could support this hypothesis. But, contrary to the theory of steric interference of TGN1112, 
the binding kinetics to isolated T cells was comparable to that of TGN1412. After 10 minutes, 
excess antibody probably did not crosslink, but was bound by one arm of the antibody (as 
shown in Figure 48C), so the detected antibody on the T cell surface was much higher. With 
time it reached binding equilibrium, achieving probably maximum level of CD28 crosslinking 
(Figure 48B). Lower antibody concentrations behaved as shown in Figure 48A, and after 4h it 
reached crosslinking equilibrium. The fact that initial binding of excess antibody gave double 
the MFI value than after reaching equilibrium (4h) supports the hypothesis of CD28SA 
crosslinking of CD28 homodimers (bivalent binding) on the T cell surface after initial 
monovalent binding of the antibody (Evans et al. 2005). 
 
 
Figure 48. Representation of the Heidelberger-Kendall curve with TGN1412 Fab2 
proliferative response. The grey line represents the calculated percentage of maximum 
proliferative response from the experiment shown in Figure 35 and the black line a fitted 
bell-shaped curved of a classical Heidelberger-Kendall curve. A. Area of ligand (CD28) 
excess. B. Equivalence zone, where maximum response is reached due to crosslinking 
equilibrium. C. TGN1412 Fab2 excess. 
    
The difference between TGN1112 and TGN1412 T-cell activation cannot be explained 
by different binding kinetics. Instead, the Fc portion does seem to play an unexpected 
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negative role. The binding kinetics on intact PBMC showed a different pattern than on 
purified T cells. TGN1112 seemed to be being ripped-off from the T-cell surface, a 
phenomenon seen as well, but to a much lower degree, for TGN1412, and not at all for the 
Fab or Fab2 fragments of either CD28SA. As discussed, the Fc portion of TGN1112 is much 
more available than that of TGN1412 (Figure 47), and it also presents higher binding affinity 
to Fc receptors (Presta and Namenuk 2005). It seems that monocytes and other FcR-positive 
cells are ripping off CD28-TGN1112 complexes from the T-cell surface by Fc-FcR mediated 
interactions, even in the presence of human serum which contains high Igs concentrations. 
Qureshi et al. (2011) reported a similar phenomenon on CTLA-4 positive cells, termed trans-
endocytosis, in which the cells ripped-off its ligands (CD80/CD86) from the surface of 
dendritic cells, which seems to be another regulatory mechanism of CTLA-4 to block CD28 
costimulation.  
The fact that TGN1112 might be being removed from the T cell surface could account 
for the lack of stimulatory capacity, since proliferation was measured from day 2-3, and 
cytokines in the supernatant after 24h of stimulation. Using a shorter and more sensitive 
read-out (ELISPOT, 16h stimulation) allowed detecting cytokine release (IFN-#) induced by 
intact TGN1112, still lower than Fab2 fragments.  
 
In conclusion, the RESTORE protocol is a straightforward, simple and practical method 
that allows circulating T cells to recover the functional pre-activation state that they have in 
lymph nodes and tissues (Figure 49). It allows, for the first time, to reproduce in vitro the 
cytokine storm that TGN1412 elicited during the first-in-man clinical trial in London in 2006. 
This method also renders T cells more sensitive to stimulation or less sensitive to blockade 
with different substances, showing the relevance of its use on the testing of novel T cell 
directed drugs. On a more general note, the RESTORE protocol could improve greatly the 
predictive value of T cell directed assays in preclinical trials, as well as allowing drug testing 
on an individualized or personalized level. 
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Figure 49. T-cell response to soluble TGN1412 takes place within the dense 
environment in tissues. Circulating lymphocytes are not in contact with DC, so they do not 
receive tonic signals. Tissues have a highly packed environment where lymphocytes come in 
close contact with DC, which they scan for cognate antigen via MHC-TCR interactions, 
receiving tonic signals that renders them more sensitive, and therefore TGN1412 reactive 
(Hünig 2012)¶. 
 
                                                
¶
 Reprinted from Nature Reviews Immunology, 12/5, Thomas Hünig, The storm has cleared: lessons from the 
CD28 superagonist TGN1412 trial, 317-318, 2012, with permission from Nature Publishing Group. 
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Annex 
Materials 
Chemicals and reagents 
Chemical / reagent Manufacturer 
10X Permeabilization Buffer eBioscience 
ß-mercaptoethanol Invitrogen  
Agarose AppliChem 
Amplifying solution Perkin Elmer 
Anti-FITC microbeads Miltenyi Biotec 
Anti-PE microbeads Miltenyi Biotec 
BD FACSRinse Solution BD Biosciences 
Brefeldin A Sigma 
Bovine Serum Albumin (BSA) Roth 
CD14 microbeads human Miltenyi Biotec 
Dexamethasone Sigma 
Dimethylsulfoxide (DMSO) AppliChem 
DNase (Benzonase) Merck KGaA 
Ethanol AppliChem 
Fixation / Permeabilization Concentrate eBioscience 
Fixation / Permeabilization Diluent eBioscience 
Perm/Wash eBioscience 
Perm/Wash BD 
Gigasept Instru AF Schülke & Mayr 
Goat anti-mouse IgG microbeads Miltenyi Biotec 
HEPES AppliChem 
Isopropanol Roth 
Lymphocyte separation medium PAA 
NBT/BCIP Liquid Substrate System Sigma 
Non-essential amino acids Invitrogen  
Paraformaldehyde Sigma 
SDS Roth 
Sodium azide (NaN3) Roth 
Sodium pyruvate Invitrogen  
TEMED AppliChem 
Triton X-100 Roth 
Trypan blue Sigma 
Tween-20 AppliChem 
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Enzymes and inhibitors  
Name Abbreviation Manufacturer 
Sodium orthovanadate  Na-O-Vanadate Roth 
Sodium fluoride NaF Sigma-Aldrich 
Dithiothreitol DTT Roche 
Phenylmethanesulphonylfluoride PMSF Roche 
Protease inhibitor tablet / 
Complete mini 
- Roche 
Cyclosporin A CsA Calbiochem 
PP1 analog PP1 Calbiochem 
 
Commercial kits 
Kits Manufacturer 
CD4+ T Cell Isolation Kit II Miltenyi Biotec 
Human IL-10 Flex Set BD Biosciences 
Human IL-2 Flex Set BD Biosciences 
Human INF-# Flex Set BD Biosciences 
Human TNF Flex Set BD Biosciences 
Human Soluble Protein Master Buffer Kit BD Biosciences 
Monocyte Isolation Kit II Miltenyi Biotec 
 
Magnetic beads for cell isolation or depletion 
Beads Manufacturer 
Anti-PE microbeads Miltenyi Biotec 
Anti-FITC microbeads Miltenyi Biotec 
 
Radioactive materials 
Name Isotope Manufacturer 
[3H]-thymidine Tritium  Hartmann Analytic GmbH 
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Antibodies and secondary reagents 
 
Primary and secondary antibodies 
Antigen Clone Conjugation Isotype Manufacturer 
HLA-DR,DP,DQ Tü39 Purified mIgG2a, ( Kind gift of Prof. 
Rammansee, 
Tübingen, 
Germany 
HLA-ABC W6/32 Purified mIgG2a, ( 
Anti-
Phosphotyrosine 
4G10 FITC Mouse IgG2b, k Millipore 
h CCR7  3D12 FITC Rat IgG2a, k BD 
h CCR7 3D12 PE Rat IgG2a, k BD 
h CCR7 3D12 Alexa647 Rat IgG2a, k BD 
h CD14 MfP9 FITC Mouse IgG2b, k BD 
h CD14 M5E2 PE Mouse IgG2a, k BD 
h CD154 TRAP1 FITC Mouse IgG1, k BD 
h CD19 HIB19 FITC Mouse IgG1, k BD 
h CD19 HIB19 PE Mouse IgG1, k BD 
h CD247 K25-407.69 Alexa647 Mouse IgG2a, k BD 
h CD25 M-A251 FITC Mouse IgG1, k BD 
h CD25 M-A251 PE Mouse IgG1, k BD 
h CD28 CD28.2 Alexa488 Mouse IgG1, k Biolegend 
h CD28 CD28.2 PECy5 Mouse IgG1, k BD 
h CD3 UCHT1 Alexa647 Mouse IgG1, k BD 
h CD4 RPA-T4 PECy5 Mouse IgG1, k BD 
h CD4 RPA-T4 PECy5 Mouse IgG1, k Biolegend 
h CD4 M-T477 FITC Mouse IgG2a, k BD 
h CD45 H130 Alexa647 Mouse IgG1, k Biolegend 
h CD45RO UCHL1 FITC Mouse IgG2a, k BD 
h CD45RO UCHL1 APC Mouse IgG2a, k BD 
h CD45RO UCHL1 APC Mouse IgG2a, k Biolegend 
h CD56 B159 PE Mouse IgG1, k BD 
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Antigen Clone Conjugation Isotype Manufacturer 
h CD69 FN50 PE Mouse IgG1, k BD 
h CD69 FN50 PE Mouse IgG1, k Biolegend 
h CD8 RPA-T8 FITC Mouse IgG1, k BD 
h CD8 RPA-T8 PE Mouse IgG1, k BD 
h CD80 L307.4 FITC Mouse IgG1, k BD 
h CD83 HB15e PE Mouse IgG1, k BD 
h CD86 2331 (FUN-1) PECy5 Mouse IgG1, k BD 
h CD95 DX2 FITC Mouse IgG1, k BD 
h Foxp3 259D/C7 Alexa488 Mouse IgG1 BD 
h HLA-ABC G46-2.6 FITC Mouse IgG1, k BD 
h HLA-DR G46-6 FITC Mouse IgG2a, k BD 
H HLA-DQ Tu169 FITC Mouse IgG2a, k BD 
h IL-2 MQ1-17H12 PE Rat IgG2a, k BD 
h INF-# 4S.B3 PE Mouse IgG1, k BD 
h kappa Ig G20-193 PE Mouse IgG1, k BD 
h Ki67 B56 PE Mouse IgG1, k BD 
h Ki67 Ki-67 PE Mouse IgG1, k Biolegend 
h TCR #% B1 PE Mouse IgG1, k BD 
h TNF MAb11 PE Mouse IgG1, k BD 
h TNF-a MAb11 FITC Mouse IgG1, k Biolegend 
m IgG  (H+L) Polyclonal PE Donkey IgG Fab2 
fragment 
Dianova 
m IgG1, k  
Isotype control 
MOPC-21 PE Mouse IgG1, k Biolegend 
h: human     m: mouse 
 
Antibodies for ELISPOT 
Antibody Format Manufacturer 
Human IFN-# ELISpot pair Capture antibody:  
purified anti-human IFN# 
BD Biosciences 
Detection antibody:  
biotinylated anti-human IFN# 
BD Biosciences 
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Antibody Format Manufacturer 
Human IL-2 ELISpot pair Capture antibody:  
purified anti-human IL-2 
BD Biosciences 
 Detection antibody:  
biotinylated anti-human IL-2 
BD Biosciences 
Human TNF ELISpot pair Capture antibody:  
purified anti-human TNF 
BD Biosciences 
 Detection antibody:  
biotinylated anti-human TNF 
BD Biosciences 
  
Antibodies for Western Blot 
Antigen Clone Conjugate Isotype Manufacturer 
CD3-$ 6B10.2 Purified Mouse IgG2a, k Santa Cruz 
Phosphotyrosine 4G10 Purified Mouse IgG2b, k Millipore 
 
Secondary reagents 
Reagent Conjugation Manufacturer 
Streptavidin HRP BD Biosciences 
Streptavidin AP Southern Biotech 
 
Cell stimulation-related reagents 
Name Manufacturer 
Brefeldin A Sigma 
CD2 antibodies (M1, M2, 3PT) Kind gift from De Jutta Schröder-Braunstein, 
Heidelberg, Germany 
Human Serum Type AB from Male AB Sigma 
Lectin from Phaseolus vulgaris 
Phytohemagglutinin PHA-P 
Sigma 
Methylprednisolone (Urbason) Sanofi Aventis 
Muromonab-CD3 (OKT3) Janssen-Cilag 
Tetanus diphtheria toxoid (Td) (Td-Impfstoff 
Mérieux) 
Sanofi Pasteur MSD 
TGN1412 (TAB08) Theramab GmbH 
Tuberculin purified protein derivate (PPD) Statens Serum Institut 
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Buffers, media and solutions 
 
BSS (balanced salt solution) / 0.2% BSA (bovine serum albumin) (BSS/BSA) 
  BSS I    1100 mL 
  BSS II    1100 mL 
  BSA    20.0 g 
  ddH2O   ad 10.0 L 
 
 BSS I 
Glucose    100 g 
KH2PO4    6.0 g 
Na2HPO4&2H2O   23.8 g 
Phenol red    1.0 g 
ddH2O   ad 10.0 L 
 
BSS II 
CaCl2&2H2O    18.6 g 
KCl     40.0 g 
NaCl     800 g 
MgCl2&6H2O    20.0 g 
MgSO4&7H2O    20.0 g 
ddH2O   ad 10.0 L 
 
Citrate buffer 
  Citric acid   0.1 M 
  Sodium citrate   0.1 M 
 Adjust pH to 6.0 
 
FACS buffer  
  BSA    0.1% 
  Sodium azide   0.01% 
In PBS 
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Freezing medium 
Heat-inactivated human AB serum 50% 
AB medium (w/o human AB serum) 40% 
DMSO     10% 
Sterile filter. Freezing medium is good for two weeks if stored at 4°C. 
 
Lysis buffer 
  Tris.Cl pH 8.0   50 mM 
  NaCl    150 mM 
  Triton X-100   1% 
  Protease and phosphatase inhibitors: 
   Complete mini  4% 
   Na-O-Vanadate 1 mM 
   NaF   1 mM 
   DTT   1 mM 
   PMSF   0.1 mM 
 In ddH2O 
 
PBS (Phosphate buffered saline) 
  NaCl    80.0 g 
  KCl    2.0 g 
  KH2PO4   2.0 g 
  Na2HPO4    11.5 g 
ddH2O   ad 10.0 L 
Adjust pH to 7.4 
 
RPMI + 10% AB serum (AB medium) 
RPMI + 2 mM L-Glutamine      500 mL 
Penicillin / Streptomycin (100 U/mL)   ca 1.2 mL 
Non-essential amino acids (100X MEM)   5.0 mL 
Na-Pyruvate (100 mM)     5.0 mL 
'-Mercaptoethanol (50 mM)     500 µL 
HEPES (1 M)       5.0 mL 
10% heat inactivated human AB serum (or autologous) 50 mL 
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Versene 
KCl   1.0 g 
KH2PO4   1.0 g 
NaHPO4   2.84 g 
NaCl    41.0 g 
Versene   1.0 g 
  ddH2O  ad 5.0 L 
 
Human cells 
Cell type Source Location 
Human PBMC Venous blood Institute of Transfusion Medicine 
and Hemotherapy, University 
Clinic Würzburg, Germany 
Human lymph nodes Para-iliac region of renal 
transplant recipients 
Renal Transplant Unit, 
Department of Medicine, 
Academic Medical Center, 
Amsterdam, The Netherlands 
 Pancreas of non-diabetic brain-
dead multi-organ donors 
Islet Isolation Facility, San 
Raffaele Hospital, Milan, Italy 
 
Equipment and supplies 
Equipment / Supplies Manufacturer Specifications 
10 µL tips Roth  
1000 µL blue tips Roth  
200 µL yellow tips Roth  
24 well plates Greiner Bio-One Flat bottom cell culture 
48 well plates Greiner Bio-One Flat bottom cell culture 
96 well plates Greiner Bio-One Flat bottom cell culture 
96 well plates Greiner Bio-One U bottom suspension culture 
Cell strainer  BD Falcon 70 µm Nylon 
Centrifuge Eppendorf Eppendorf centrifuge 5804 R 
Centrifuge Heraus Heraus Megafuge 1.0R 
Cryotubes Nunc Cryotube Vials 1.8 mL 
Cuvette Bio-Rad  
Dispenser tips Brand 1.25 mL, 2.5 mL 
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Equipment / Supplies Manufacturer Specifications 
Confocal microscope Zeiss Laser Scan Microscope, LSM510 Meta, 
equipped with an inverted Zeiss Axiovert 
200M stand 
ELISPOT plates Millipore MultiScreen Filter plates (white) 
ELISPOT reader C.T.L. ImmunoSpot S5 Versa Analyzer 
FACS tubes BD Biosciences REF 352052 
 Hartenstein RE03 
Centrifuge tubes Greiner Bio-One 15, 50 mL polypropylene 
Flow cytometer BD Biosciences FACSCalibur 
Flow cytometer BD Biosciences LSR II 
Freezing container Nalgene “Mr Frosty”, 18 vials 
Harvester Perkin Elmer LAS GmbH  
Humidified incubator Thermo Scientific HERA Cell 150 
Laminar flow hood Antair Antair ZKB hood 
 Hera Cell Hera safe hood 
Leucosep tubes Greiner Bio-One 50 mL 
Liquid scintillation counter Perkin Elmer LAS GmbH MicroBeta Liquid Scintillation Counter 
MACS separation columns Miltenyi Biotec 25 LS and LD 
Refrigerator Liebherr Glassline 
Transwell plate Corning Incorporated 
(COSTAR) 
6.5 mm diameter inserts 
8.0 µm pore size 
Western blot membrane Roth Roti-PVDF membrane 
 
Software 
Software Application Reference 
Adobe Illustrator CS2 v.12.0.0 Figure preparation Adobe 
CELLQuest v3.3 FACS data acquisition on 
FACSCalibur flow cytometer 
BD Biosciences 
EndNote X5 Reference management Thomson Reuters 
FACSDiva Software v6.1.3 FACS data acquisition on LSR II 
flow cytometer 
BD Biosciences 
FCAP Array software v2.0 CBA results analysis SoftFlow Inc, 
www.fcaparray.com 
FlowJo v9.5.2 FACS data analysis TreeStar, Inc 
Graphpad Prism v5 for Macintosh Graphs and statistical analysis www.graphpad.com 
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Software Application Reference 
ImageJ Colocalization coefficient 
analysis of confocal microscopy 
images 
rsbweb.nih.gov/ij/ 
Image Reader LAS-3000 v2.0 Dark Box image acquisition Fujifilm 
ImmunoSpot reader systems Read ELISPOT plates C.T.L. 
ImmunoSpot software v4.0 Analyze ELISPOT images C.T.L. 
Microbeta Windows Workstation v2 Liquid scintillation counting Perkin Elmer LAS 
GmbH 
Microsoft Office 2011 for MAC Data management, manuscript 
preparation 
Microsoft 
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List of abbreviations and acronyms 
 
°C Degrees Celsius 
AP Alkaline Phosphatase 
AP-1 Activator Protein 1 
-APC Allophycocyanin 
APC Antigen-Presenting Cell 
B-CLL B-cell Chronic Lymphocytic Leukemia 
BCR B-cell receptor 
BSA Bovine Serum Albumin 
BSS Balanced Salt Solution 
BTLA B- and T-Lymphocyte Attenuator 
CBA Cytometric Bead Array 
CD Cluster of Differentiation 
CDR Complementarity-Determining Region 
CFSE Carboxyfluorescein diacetate, Succinimidyl Ester 
CLL Chronic Lymphocytic Leukemia 
cpm Counts per Minute 
CRS Cytokine Release Syndrome 
CTLA-4 Cytotoxic T-Lymphocyte Antigen 4 or CD152 
ddH2O Double distilled water 
DNase Deoxyribonuclease 
ELISpot Enzyme-Linked Immunospot Assay 
EMA European Medicines Agency 
Fab Fragment antigen binding 
FACS Fluorescence-Activated Cell Sorter/-ing 
Fc Fragment Crystallizable  
FcR Fc receptor 
FCS Fetal Calf Serum 
FITC Fluorescein Isothiocyanate 
FoxP3 Forkhead box P3 
g Grams 
GMP Good Manufacturing Practice 
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Grb2 Growth factor Receptor-bound protein 2 
GvHD Graft-versus-Host Disease 
h Hours 
HLA Human Leukocyte Antigen 
HRP Horseradish Peroxidase 
IFN-# Interferon gamma 
Ig Immunoglobulin 
IL Interleukin  
IL-#R IL-# Receptor 
IP  Immunoprecipitation 
ITAM Immunoreceptor Tyrosine-based Activating Motif 
kD Kilodalton 
L Liter 
Lck Lymphocyte-specific protein tyrosine kinase 
LFA-1,3 Lymphocyte Function-associated Antigen 1 or 3 
LN Lymph Nodes 
LRS-C Leukoreduction System Chambers 
mA Milliampere 
MABEL Minimum Anticipated Biological Effect Level 
MFI Mean Fluorescence Intensity 
min. Minutes 
mL Milliliter 
mRNA Messenger Ribonucleic Acid 
NFAT Nuclear Factor of Activated T cells 
NF(B Nuclear Factor kappa-light-chain-enhancer of activated B 
cells 
NOAEL No Observed Adverse Effect Level 
O/N Overnight 
OKT3 Muronomab – Orthoclone OKT3 
PBMC Peripheral Blood Mononuclear Cells 
PBS Phosphate Buffered Saline 
PD-1 Programed-Death receptor 1 
PE Phycoerythrin 
PECy5 Phycoerythrin-Cy5 
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pg Picograms  
PI3K Phosphatidylinositol 3 kinase 
PKC-' Protein Kinase C theta 
PPD Tuberculin Purified Protein Derivate 
RT Room Temperature 
SD Standard Deviation 
SDS-PAGE Sodium Dodecyl Sulfate-Polyacrylamide Gel 
Electrophoresis 
sec. Seconds 
SMAC Supramolecular Activation Cluster 
Td Tetanus Diphtheria toxoid  
TNF Tumor Necrosis Factor 
TNFRII Tumor Necrosis Factor Receptor II 
V Volts 
x g  Relative centrifugal force (RCF, g-force) 
ZAP-70 Zeta-chain Associated Protein kinase of 70 kD 
# Alfa  
µ Micro 
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